Impact of Acute and Chronic Hyperglycemia on Vasoconstrictor Responses of Retinal Venules: Role of Reverse-Mode  Sodium-Calcium Exchanger by Chen, Yen-Lin
IMPACT OF ACUTE AND CHRONIC HYPERGLYCEMIA ON 
VASOCONSTRICTOR RESPONSES OF RETINAL VENULES: 




Submitted to The Office of Research and Graduate Studies of 
The Texas A&M University System Health Science Center 
in partial fulfillment of the requirements for the degree of 
DOCTOR OF PHILOSOPHY 
Chair of Committee, Lih Kuo 
Co-Chair of Committee, Travis W. Hein 
Committee Members, Robert H. Rosa, Jr. 
Shenyuan L. Zhang 
Head of Program, Warren E. Zimmer 
May 2019 
Major Subject: Medical Sciences 
Copyright 2019 Yen-Lin Chen 
 ii 
ABSTRACT 
             Hyperglycemia, a hallmark of diabetes, is associated with increased retinal fluid 
filtration, a process heavily influenced by the postcapillary pressure and venous constriction. In 
hyperglycemia/diabetes, the serum level of vasoconstrictors endothelin-1 (ET-1) and 
thromboxane A2 (TXA2) are elevated, and ET-1 has been implicated in retinal venous 
pathologies such as diabetic retinopathy and retinal vein occlusion. However, their impacts and 
mechanistic actions on venular vasomotor activity in the retina with hyperglycemic/diabetic insult 
remain unclear. First, we characterized the mechanistic action of ET-1 on isolated porcine 
retinal venules by examining the roles of ET-1 receptors, extracellular calcium (Ca2+), L-type 
voltage-operated calcium channels (L-VOCCs), Rho kinase (ROCK), and protein kinase C 
(PKC) in ET-1-induced vasoconstriction. We found that extracellular Ca2+ entry via L-VOCCs is 
essential for developing and maintaining basal tone of porcine retinal venules. ET-1 causes 
significant constriction of retinal venules by activating endothelin A receptors (ETARs) and 
extracellular Ca2+ entry independent of L-VOCCs. Activation of ROCK signaling, without 
involvement of PKC, appears to mediate venular constriction to ET-1 in the porcine retina. 
Second, we found that chronic hyperglycemia (diabetes) and acute hyperglycemia (incubating 
the vessels with 25 mM glucose for 2 hours) significantly enhanced retinal venular constriction 
to ET-1, norepinephrine, and TXA2 analogue U46619. Angiotensin II and phenylephrine elicited 
insignificant constriction of retinal venules. Moreover, the receptor mRNA expressions for ET-1, 
TXA2, and α2A-adrenoceptor were not altered in diabetic venules, but the ET-1 level in vitreous 
humor was elevated in diabetic animals. After exposure to a high glucose (25 mM), the isolated 
human retinal arterioles also exhibited enhanced constriction to ET-1. Administration of both 
reverse-mode sodium-calcium exchanger (NCX) inhibitor KB-R7943 and sodium hydrogen 
exchanger (NHE) blocker cariporide did not affect the vasoconstriction to ET-1 in normal 
vessels but abolished the enhanced constriction to ET-1 in diabetic venules. Overall, our 
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findings indicate that both chronic and acute hyperglycemia augment constriction of retinal 
venules to ET-1, U46619, and norepinephrine, via activation of both reverse-mode NCX and 
NHE. It is speculated that the enhanced venular response to these vasoconstrictors may 
increase capillary filtration by elevating postcapillary venular pressure during the early stage of 
diabetes. These pathophysiological changes may consequently promote tissue edema and 
development of diabetic retinopathy, in addition to the reduction of ocular perfusion. Blockade of 
reverse-mode NCX and NHE in retinal venules might provide a new therapeutic strategy to 
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             Hyperglycemia, a hallmark of diabetes, is associated with increased retinal fluid 
filtration,1 a process primarily governed by the postcapillary pressure and venous resistance, 
which is dictated by the vasomotor activity of muscular venules and veins. The constriction of 
venous vessels could lead to elevated venous resistance and capillary pressure, consequently 
facilitating fluid filtration.2,3 Without appropriate treatment and control, the changes in venous 
circulation would consequently promote vision impairment due to edema and other 
complications. The clinical evidence has shown increased retinal venous pressure and 
decreased retinal blood flow in patients with diabetic retinopathy.4,5 However, it is unclear 
whether diabetes or hyperglycemia alters vasomotor responses of retinal venules to 
endogenous vasoconstrictors. Accumulating evidence has shown elevated endothelin-1 (ET-1) 
levels in the vitreous humor and plasma in human patients with proliferative diabetic 
retinopathy,6 and in retinal tissue of diabetic rats.7,8 Elevated expression levels of other 
vasoconstrictors, such as thromboxane A2 (TXA2),9 norepinephrine10 and angiotensin II,11 have 
been detected in plasma/serum or retinal tissue of experimental models of diabetes. Therefore, 
it is important to investigate the effects of these endogenous vasoconstrictors in the vasomotor 
response of retinal venules during diabetes/hyperglycemia. 
             It is generally accepted that Ca2+ entry plays an important role in the vascular smooth 
muscle cells triggering vasoconstriction.12 In some blood vessels, activation of L-type voltage-
operated calcium channels (L-VOCCs)12 and calcium release-activated calcium (CRAC) 
channels13 have been demonstrated in this process. However, it remains unclear whether these 
channels contribute to the constriction of retinal venules. Another possible route for Ca2+ entry is 
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the activation of the reverse mode sodium-calcium exchanger (NCX).14 Interestingly, the study 
in cardiomyocytes has demonstrated that ET-1 can exert an inotropic effect by eliciting 
extracellular Ca2+ influx through coupling of the sodium-hydrogen exchanger (NHE) with 
reverse-mode NCX.14 Moreover, exposure of cardiomyocytes to a high level of glucose can 
activate the reverse-mode NCX and lead to increased Ca2+ entry.15 Activation of NHE in 
diabetes appears to have an adverse impact on the retinal arterial circulation.16 However, the 
putative role of NCX and NHE-NCX in mediating venular pathophysiology, especially under 
hyperglycemic/diabetic insult, in the retina remains to be determined. Although clinical evidence 
has shown increased retinal venous pressure in human patients with diabetic retinopathy,4 there 
is no information on how venular reactivity to vasoconstrictors is influenced by hyperglycemia in 
the human retina. Herein, the goals of these studies were to investigate the mechanistic action 
of ET-1 and other vasoconstrictors (U46619, norepinephrine, phenylephrine, and angiotensin II) 
on isolated porcine retinal venules under normal and diabetic/hyperglycemic conditions, and to 
examine whether the reverse mode NCX and NHE are involved in the vasomotor regulation. 
The vasomotor reactivity of human retinal venules in response to ET-1 was also investigated in 
vitro under normal and hyperglycemic conditions, as an attempt to support the use of the 
porcine model for studying the human retinal microcirculation. 
 3 
Significance  
             The venular vasculature is the most effective vessel in the circulation, in terms of 
regulating capillary pressure and tissue fluid homeostasis, by altering its activity, i.e., resistance, 
through constriction or dilation.17 However, there are few studies focusing on the vasomotor 
responses and the mechanistic actions of vasoconstrictors in retinal venules. Overproduction of 
vasoconstrictors is known to contribute to the pathogenesis of many diseases, including 
diabetes.7,18-21 Diabetic pathogenesis is noted to be associated with increased retinal venous 
pressure and reduced retinal blood flow.5,22 It is clinically important to understand the vasomotor 
responses of retinal venules to ET-1 because the concentration and expression of this potent 
vasoconstrictor are elevated in the blood circulation23 and retinal tissues.6,24 However, there is 
no information concerning the vasomotor action of ET-1, as well as other endogenous 
vasoconstrictors (TXA2, norepinephrine and angiotensin II), on retinal venules and its 
pathophysiological contribution remains undetermined. A better characterization of the 
mechanisms involved in retinal venular reactivity and its abnormal reaction is critical in 
understanding the pathogenesis of retinal disorders, especially in the development of 
retinopathy. The present study is the first to systematically examine this important issue. I 
documented that the constrictions of retinal venules to ET-1, TXA2 and norepinephrine are 
augmented by chronic hyperglycemia (diabetes) and acute hyperglycemia (2-hour exposure to 
high glucose) through activation of the NHE-NCX pathway. In view that the venular circulation 
plays cardinal roles in determining capillary pressure and transcapillary fluid exchange, the 
enhanced vasomotor activity of the venules in diabetes can directly influence the fluid 
homeostasis of the tissue and promote the development of retinopathy. The results of my study 
may provide novel therapeutic strategies to mitigate diabetic retinopathy or diabetes-induced 
retinal tissue edema by targeting the NHE and NCX pathway. 
 
             This dissertation follows the style of Investigative Ophthalmology and Visual Sciences.
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Function of Retinal Venules 
             The ocular circulation is important in providing necessary nutrients and oxygen, 
removing metabolic waste, and thus maintaining normal vision.25 Within the ocular circulation, 
numerous investigations have demonstrated the crucial role of the retinal arteriolar system in 
the regulation of retinal blood flow.2,3,25 Most studies on the retinal venous system were about its 
architecture and basic function in the drainage pathway,25 and there is no report on the 
regulation of vasomotor activity of retinal venules under health or disease. It has been shown 
that the wall of the retinal vein (porcine model) is thin and consists of a single layer of 
endothelial cells and only a few smooth muscle cells.26 Moreover, the circumferential orientation 
of smooth muscle cells in retinal venules (non-circularly oriented) is different from retinal 
arterioles (circularly oriented).26 The existence of pericytes appearing on the surface of the 
retinal venule remains to be investigated. The potential contribution of the retinal venous 
circulation to the development of diabetic retinopathy is generally associated with augmented 
vascular permeability, retinal edema, and retinal vein occlusion,4,18,20,27-29 with the thought of 
breaking down of the blood-retinal barrier (BRB) in the venous vasculature.1,27-29 However, the 
contribution of altered vasomotor responses of retinal venules was unknown and received less 
attention. 
             Most investigators, based on the isogravimetric/isovolumetric whole-organ preparations, 






where Pciso is isogravimetric/isovolumetric capillary pressure, Pa is mean arterial pressure, Pv is 
venous pressure, Ra is arterial resistance, and Rv is venous resistance. In general, the value of 
Rv/Ra is less than 1 (value ≈ 0.330). Many studies primarily supported that Pc is tightly regulated 
in response to alteration in Pa, while Pv is held constant or remains essentially unchanged. 
However, considering the formula mentioned above with changed Pv, the venular vasculature 
becomes the most effective vessel in the circulation in terms of regulating Pc and fluid 
homeostasis. It has been shown experimentally that the change in venous pressure is about 5 
to 10 times more effective in changing capillary pressure than a similar change of pressure 
applied from the arterial side.17 It was calculated that about 80%-85% of a venous pressure 
increment is transmitted to the capillaries,17,31 with a greater emphasis on the critical role of 
venous constriction and dilation in determining capillary pressure.32 Therefore, characterizing 
the vasomotor action of retinal venules is important toward the understanding of pathogenesis 
of retinal vascular diseases. There had been no study focusing on vasomotor function of retinal 
venule until Yu and colleagues demonstrated that ET-1 and adenosine caused local 
vasoreactivity of porcine retinal veins.26 In addition, in an epidemiological study, Cybulska-
Heinrich and colleagues found a significant association between increased retinal venous 
pressure (RVP) and diabetic retinopathy.4 However, it remains unknown whether diabetes alters 
the retinal venular response to endogenous vasoconstrictor ET-1. In the following sections, I will 
first discuss the vasomotor action of endogenous vasoconstrictors, ET-1, norepinephrine, TXA2, 
and angiotensin II in the ocular circulation and then discuss the underlying mechanisms, 
gathered from other vascular beds, contributing to these vasoconstrictions.    
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Vasoactive Responses to Vasoconstrictors in the Ocular Circulation 
             In general consideration, one of the dominant effects of vasoconstrictors is the 
narrowing of the blood vessels resulting from contraction of smooth muscle cells in the vascular 
wall, in addition to evoking other biological activities, including cell proliferation, migration and 
inflammation. This process is extremely important in the event of alleviating hemorrhage and 
acute blood loss, and regulating perfusion and distribution of blood flow. Different 
vasoconstrictors may act differently in different tissues and vessel types, and the sensitivity and 
responsiveness may be vessel-size dependent.33 In this study, I will focus on the 
vasoconstrictors ET-1, TXA2, angiotensin II and norepinephrine, and will elucidate their 
vasomotor impacts in the retina because upregulation of these vasoconstrictors has been 
suggested to play a role in disease development. 
 
ET-1 
             ET-1 is a potent vasoactive peptide comprised of 21 amino acids and plays important 
roles in many biological functions, including vasoconstriction, cardiovascular remodeling, tissue 
inflammation, and cell proliferation.13,34-38 With human ocular investigation, a reduced retinal 
blood flow has been shown after intravenous administration of ET-1 in healthy subjects.39 ET-1 
and ET-3 were found in most human and porcine ocular tissues via immunoreactivity study or 
high-pressure liquid chromatography.40,41 Moreover, reduced retinal blood flow and retinal artery 
constriction in rats has been shown after intravitreal injection of ET-1.21 Interestingly, the retinal 
arterial constrictions evoked by isometric exercise in healthy humans was attenuated by 
blocking ET-1 type A receptor (ETA), suggesting the involvement of ET-1 in retinal blood flow 
regulation during systemic blood pressure changes.42 A number of studies have demonstrated a 
potent vasoconstrictor effect of ET-1 in isolated porcine43-45 and human46 retinal arterioles, 
suggesting that ET-1 is capable of reducing arterial blood flow in the retina via vasoconstriction. 
In contrast to the arterioles, the action of ET-1 in the venous circulation is not well studied, and 
 7 
there is only one report demonstrating the constriction of retinal venules to ET-1 in the porcine 
eye.26 However, the underlying mechanism and the impact of hyperglycemia/diabetes on this 
venular constriction remains unknown. 
 
TXA2 
             TXA2 is one of the metabolites generated from arachidonic acid via 
cyclooxygenase/prostaglandin H2 synthase.47 Prostaglandin H2 is then converted to TXA2   
by thromboxane-A synthase.47 The activated platelets are the major source of TXA2, which has 
pro-thrombotic properties by promoting platelet aggregation and plays pathophysiological roles 
during tissue injury and inflammation.47,48 TXA2 is unstable in aqueous solution because it is 
hydrolyzed within few seconds to the biologically inactive thromboxane B2 (TXB2).49 Therefore, 
the stable TXA2 synthetic analog U46619 (9,11-dideoxy-9α,11α-methanoepoxy PGF2α) is 
widely used to assess the biological action of TXA2.50 In the ocular system, TXB2 expression 
was detected in the human vitreous humor.51 Chen and colleagues showed that TXA2 receptors 
are mainly expressed in non-pigmented epithelial cells of the ciliary body, photoreceptors, and 
the endothelium of posterior ciliary arteries.52 The TXA2 analog U46619 evokes significant 
constriction of choroidal vessels in newborn pigs.53 In isolated arterial ring segments from the 
bovine retina, U46619 has been shown to be the most potent vasoconstrictor compared to the 
other arachidonic acid derivatives, i.e., prostaglandin F2a and prostaglandin E2.54 Furthermore, 
U46619 elicits moderate constriction of isolated porcine retinal arterioles with attached 




             The renin-angiotensin system (RAS) plays important roles in regulating blood pressure 
and sodium retention in kidney.57,58 The hormone angiotensin II is the main bioactive molecule  
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of the RAS converted from angiotensin I by the enzyme angiotensin-converting 
enzyme (ACE).57 Angiotensin II can increase vasopressin production from the central nervous 
system and also causes vasoconstriction by acting on the angiotensin II receptors in the 
vasculature.57 In the ocular system, angiotensin II was detected in the anterior uveal tract, 
neural retina and retinal pigment epithelium of pigs,59 and in the porcine vitreous fluid.59 
Administration of angiotensin II caused contraction of pericytes60 in the rat retina and reduced 
pericyte-containing capillary diameter,61 and elicited voltage change in abluminal cells of the rat 
retinal microvasculature.62 In the feline retinal circulation, continuous infusion of angiotensin II 
through a transvitreal cannula placed near the retinal surface or optic nerve resulted in either 
transient or sustained constrictions of the retinal arteries.63 However, angiotensin II failed to 
evoke any vasomotor activity in isolated bovine retinal arterial rings before or after inhibition of 
prostaglandins and nitric oxide (NO), or after endothelium removal, but the vasoconstriction was 
apparent in isolated posterior ciliary arteries.64 In the isolated bovine retinal vascular network 
perfused with oxygenated physiological salt solution, topical application of angiotensin II (0.1 
mM) elicited moderate constriction of the arterial and venous vascular beds with more 
pronounced constriction in the microvessels, i.e., ~15% constriction of arterioles and ~7% 
constriction of venules from their basal resting diameters.65 Interestingly, the vasoconstriction to 
angiotensin II was enhanced by inhibiting endogenous synthesis of prostacyclin and NO.65 In 
contrast, intraluminal administration of angiotensin II caused marked dilation of the same 
vascular network.65 In retinal vascular beds, discrepancies on vasomotor response to 
angiotensin II exist, depending upon animal species, experimental approach, and methodology 
used. It appears that the vasodilators NO and prostacyclin released from the endothelium, 
under angiotensin II stimulation, may confound the contractile action of the vessel, especially in 
the retinal microcirculation. The action of angiotensin II on the retinal vasculature deserves 




             Norepinephrine, also called noradrenaline or noradrenalin, is an organic chemical 
classified in the catecholamine family and a neurotransmitter released by the sympathetic 
nerves. It is also the main hormone secreted by the adrenal medulla to regulate cardiovascular 
function.66 Many researchers have demonstrated the important role of norepinephrine in 
regulating physiological processes and the development of neurological, endocrine, and 
cardiovascular diseases mainly via activation of α-adrenergic receptors.66 Norepinephrine is 
synthesized from tyrosine by a series of enzymatic reactions and then converted from dopamine 
by dopamine β-monooxygenase.66,67 The metabolic synthesis of norepinephrine is presented 
below:  
                 
                 Phenylalanine → Tyrosine → L-DOPA → Dopamine → Norepinephrine 
             
             Catecholamines (dopamine, norepinephrine, and epinephrine) and their metabolites 
are detectable in human vitreous humor and their metabolites have been considered as 
biomarkers to identify antemortem cold stress and fatal hypothermia in forensic examination.68,69 
Among α-adrenergic receptors, predominance of the α2A subtype has been reported in human 
ocular tissue homogenates.70 In agreement with the human data above, porcine retinal 
arterioles appear to express mainly a2A receptor message and the a1 subtype was reported to 
be undetectable.71 The existence of adrenergic retinal neurons in rats and monkeys,72 and the 
expression/distribution of α-adrenergic receptor subtypes in the ocular tissue have been 
documented in various animal species, including humans.70,73 Although the specific adrenergic 
binding sites also have been identified in retinal vessels,71,74,75 their function in regulation of 
retinal blood flow remains to be determined.71,73 It has been shown that activation of α2-
adrenergic receptors by brimonidine evokes constriction of small retinal arterioles (< 60 µm in 
diameter) but dilation of upstream larger arterioles via an endothelial NO-mediated 
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mechanism.71 In addition, norepinephrine can elicit a transient and unrepeatable constriction of 
isolated bovine retinal arteries.76 Interestingly, the constriction of isolated porcine retinal 
arterioles to norepinephrine appears to be greater when the agent is applied intraluminally vs. 
extraluminally.77 The explanation for the inconsistent findings on the vasoconstrictor 
characteristics between bovine and porcine studies above is unclear. Nevertheless, the 
constriction of small retinal arterioles to adrenergic receptor activation is rather moderate33,77 
and its physiological and pathophysiological roles remain to be determined.  
             The α1-adrenergic receptor subtypes (α1A, α1B and α1D) in retinal arteriole have been 
detected in mice.74 Activation of the α1-adrenergic receptor by phenylephrine evokes 
constriction of rabbit retinal arteries and causes glutamate-induced neuronal cell death.78 In 
enucleated bovine eyes, application of phenylephrine directly onto the surface of the vessel wall 
caused constriction of main retinal arteries and veins, as well as some of their small branches.79 
However, in this in-situ preparation, the vasoconstrictions were observed in the absence of 
vascular lumenal pressure and under a supra-pharmacological concentration (0.1 mM) of 
phenylephrine. The physiological interpretation of this vasoconstrictor effect is uncertain. On the 
other hand, the main retinal arterial segments isolated from the bovine eye had no response to 
phenylephrine and only a small and inconsistent transient constriction was observed with higher 
phenylephrine concentrations (1 µM and 10 µM).80 Interestingly, the extent of vasoconstriction 
to phenylephrine was increased after a circumferential stretch was imposed on the vascular wall 
or a high concentration of membrane depolarization agent KCl (125 mM) was used to 
preconstrict the vessel.80 It appears that pre-activation of the vascular smooth muscle with a 
physical force (stretch) or chemical (depolarization agent) is required to evoke the constriction of 
bovine retinal arteries to phenylephrine. In a human study, instillation of eye drops containing 
phenylephrine caused a reduction of vessel density (assessed by optical coherence tomography 
angiography) in the peripapillary area, but not in the macular area of the retina.81 This clinical 
study may suggest a site-dependent retinal vessel constriction (i.e., reducing vascular perfusion 
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density) to α1-adrenergic activation, although the explanation for this heterogenous vascular 
responsiveness is unclear. Interestingly, topical instillation of phenylephrine can reduce blood 
velocity in the optic nerve head of monkeys but not in the central retinal artery of humans.82 
Although inconsistent vasomotor responses of retinal arteries to phenylephrine are noted, the 
vasoconstriction, if it occurs, appears to be small compared to that evoked by TXA2, 
norepinephrine, and ET-1 as discussed above. Nevertheless, it remains unclear whether retinal 
venules respond to phenylephrine.  
 
Mechanistic Pathway and Calcium-Dependent Vasoconstriction 
             Vasoconstrictor agonists may have similar or different mechanistic pathways mediating 
smooth muscle activity in different vascular beds (tissue/organ), types (artery vs. vein), or size 
(conduit vs. resistance vessel). Although it is not completely understood, in this section the G-
protein-coupled receptors-dependent vasoconstrictions to ET-1, TXA2, angiotensin II, 
norepinephrine, and phenylephrine, will be discussed based on the available literature 
concerning the general signal transduction pathways and specific vasoconstriction mechanisms. 
 
ET-1 
             Previous studies in different organ systems and vascular beds have suggested that 
vasoconstriction to ET-1 is mediated by the activation of its receptors (ETA and/or ETB), 
elevation of intracellular Ca2+, and signaling through Rho kinase (ROCK) and/or protein kinase 
C (PKC).13,35,36 The detailed signaling mechanisms are described as follows (Figure 1). In 
general, ETBRs expressed in endothelial cells can exert vasomotor function via production of 
vasodilators (NO or PGI2) and via clearance of ET-1 to mitigate excessive ETAR-dependent 
activity.13,35 In porcine retinal arterioles, ET-1 predominantly elicits vasoconstriction via the 
activation of ETARs in smooth muscle.43 The component of vasodilation via endothelial released 
NO by ETBR activation is rather minor, and activation of ETBR in the smooth muscle cells 
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exclusively produces vasoconstriction.43 With current knowledge, stimulation of ETARs with ET-1 
causes contraction of vascular smooth muscle cells through Gq/11 protein-mediated and G12/13 
protein-mediated activation.13 Upon Gq/11 protein-mediated activation, phospholipase C (PLC) is 
activated and sequentially leads to inositol triphosphate (IP3) and diacylglycerol (DAG) 
production, which then results in increased intracellular Ca2+ release and PKC activation, 
respectively.13 The binding of Ca2+ with calmodulin, in association with activation of PKC 
isoforms, ultimately activates myosin light chain kinase (MLCK) and inhibits myosin light chain 
phosphatase (MLCP), respectively, leading to vasocontraction.35,83 On the other hand, upon 
G12/13 protein-mediated activation, the Rho-GTPase is activated by several different guanine 
nucleotide exchange factors for Rho. Subsequently, Rho-GTPase activates Rho kinase (ROCK) 
and promotes smooth muscle contraction by inhibiting myosin light chain phosphatase.13,83 
             It is generally thought that sustained vasoconstriction to ET-1 requires elevation of 
cytosolic Ca2+ via extracellular influx and/or intracellular release.13,35,44,84-86 As mentioned above, 
the elevation of cellular IP3 and DAG, via Gq protein-linked PLC-β, could subsequently activate 
Ca2+ channels in a voltage-dependent and/or -independent manner.13 Binding of IP3 to its 
receptor on the endoplasmic reticulum (ER) triggers the release of Ca2+ from this store. It is 
widely accepted that the depletion of Ca2+ within the ER produces a sustained increase in 
cytosolic Ca2+ signaling through the activation of store-operated calcium channels (SOCs), such 
as Ca2+ release-activated calcium (CRAC) channels.13,35 The DAG can also activate receptor-
operated Ca2+ channels for extracellular Ca2+ entry.13 Moreover, transient receptor potential 
canonical (TRPC) channels, permeable to Ca2+ in addition to Na+, can function as SOCs.13,87,88 It 
has been shown that ET-1 can trigger Na+ influx (membrane depolarization) via the opening of 
TRPC,13 and consequently activate L-VOCC and possibly the reverse-mode NCX for Ca2+ 
entry.13,87,89,90 Several studies have demonstrated that vascular smooth muscle cell L-VOCC 
currents are positively modulated by PKC activity.91-94 However, the roles of ETAR, ETBR, PKC, 
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ROCK, L-VOCC, and reverse-mode NCX in mediating vasomotor responses to ET-1 in retinal 

















Figure 1. Role of ETAR-mediated signaling in the regulation of vascular tone. PLC, 
phospholipase C; IP3, inositol 1,4,5-trisphosphate; DAG, diacylglycerol; CaM, calmodulin; 
MLCK, myosin light chain kinase; MLC, myosin light chain; MLC-P, phosphorylated MLC; 
MLCP, myosin light chain phosphatase; ROCK, Rho-associated protein kinase (Figure modified 
from Horinouchi T, Terada K, Higashi T, Miwa S. Endothelin receptor signaling: new insight into 




             In humans, but not in rodents, there are two major G protein-coupled receptor isoforms, 
TPα and TPβ, involved in the signaling of TXA2 by activating and inhibiting adenylyl cyclase, 
respectively.95 In most cell types, the expression of TPα mRNA is more predominant than TPβ.96 
The TXA2/TP interaction involves mainly two types of G-proteins: Gq and G12/13.97,98 TP receptors 
are coupled with Gq, which initiates the PLC-IP3/PKC signaling cascade.98 On the other hand, 
TP-coupled G12/13 activates Rho kinase as a major signaling pathway leading to contraction of 
smooth muscle cells.98 Previous studies have suggested that L-type Ca2+ channels and SOC 
channels contribute to extracellular Ca2+ influx leading to TXA2 receptor-mediated contraction of 
smooth muscle in rodent models.99 There is sparse information on the vasomotor action of TXA2 
in the retinal circulation. Nevertheless, TXA2 analogue, U46619, appears to constrict bovine100 
and human101 retinal arterioles. However, whether retinal venules react to TXA2 and the 
potential underlying signaling mechanisms remain unclear.  
 
Angiotensin II 
             Angiotensin II acts through at least two types of receptors, termed AT1 
(vasoconstriction) and AT2 (vasodilation).58,102 AT1 receptors have been suggested to mediate 
most of the physiological actions of angiotensin II, and it is the predominant receptor subtype 
responsible for the control of vascular functions.58 The interaction of angiotensin II and AT1 
mainly involves two types of G-proteins: Gq and G12/13.58 AT1 receptors coupled with Gq initiates 
the PLC-IP3/PKC signaling cascade.58 On the other hand, AT1 receptors coupled with G12/13 
activates Rho kinase as a major signaling pathway leading to contraction of smooth muscle 
cells.103 These signaling pathways are similar to that elicited by TXA2/TP stimulation, i.e., the 
PLC-IP3/PKC signaling cascade.58,103 It appears that IP3 triggers Ca2+ release from the ER and 
subsequently contributes to vasoconstriction.58 Interestingly, DAG, through PKC signaling 
cascade, might elevate cytosolic Ca2+ for vasoconstriction via activation of reverse-mode NCX 
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in a manner linking to NHE and/or Na+/Mg2+ exchanger.58 In addition, Arun and colleagues have 
shown the relevant impact of L- VOCC in angiotensin II-induced vasoconstriction.104 It remains 
unclear whether the signaling pathways discussed above contribute to the retinal venular 
constriction to angiotensin II.  
 
Norepinephrine 
             Two families of adrenergic receptors have been identified as α (α1 and α2 subtype) and 
β (β1, β2, and β3 subtype) in response to the binding of norepinephrine.105 Phenylephrine is a 
selective α1-adrenergic receptor agonist.105 The G proteins involved in adrenergic receptor (AR) 
signaling include Gs, which couples with β-ARs to activate adenylyl cyclase and elevate cAMP. 
The coupling of Gi with α2-ARs can inhibit adenylyl cyclase and decrease cAMP. For α1-ARs, the 
Gq/11 family can mediate the activation of PLC-β and subsequently elevate the intracellular Ca2+ 
concentration, leading to contraction of vascular smooth muscle. The activation of α2-ARs/Gi 
could inhibit cAMP-PKA signaling and result in vascular smooth muscle contraction.105 On the 
other hand, β-ARs with Gs coupling activate the cAMP-PKA signaling cascade and elicit K+ 
channel-dependent hyperpolarization, which, in turn, promotes the closure of L-VOCC and 
subsequently leads to smooth muscle relaxation or vasodilation due to reduction of cytosolic 
Ca2+.105 The signaling pathway responsible for the adrenergic receptor activation by 
norepinephrine in the retinal venule remains unclear.   
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Retinal Blood Flow in Diabetic Retinopathy 
             From the metabolic viewpoint, the neural retina is a highly oxygen demanding tissue, 
and adequate ocular blood flow is required for its normal function.25 The retinal circulation 
provides nutritional needs and waste removal of the inner two-thirds of the highly metabolically 
active retina, and the choroidal circulation supplies the remaining retina.25 Numerous studies 
have shown that alterations in retinal blood flow are associated with open-angle glaucoma or 
diabetic retinopathy,5,106-108 which is the most common cause of vision impairment or loss 
among people with diabetes in working-age adults. Diabetic retinopathy is primarily classified in 
four stages (mild, moderate, and severe non-proliferative and proliferative).109 Intriguingly, 
previous studies have reported reduced, increased or unchanged retinal blood flow in human 
studies with diabetic retinopathy. These different patterns may be attributed to the measurement 
techniques, type of diabetes, gender of subjects, or different stages of diabetic retinopathy. The 
literature describing a link between retinal blood flow and diabetic retinopathy in humans are 
organized in chronological order in Table 1. In general, the reduction of retinal arteriolar and 
venular diameters and decrease of retinal blood flow are associated with the early stage of 
diabetes in humans, in which the results are consistent with the rodent type I diabetes studies 
(STZ injection).110,111 The manifestation of retinal blood flow reduction in early diabetes is likely 
to be a main culprit to promote development of retinopathy and retinal edema if the venular 
circulation is impacted by the development of the disease. A better understanding of the 
alteration of retinal blood flow regulation is essential and important to the management of 
progression of diabetic retinopathy and the development of strategies for therapeutic treatment. 
Therefore, it is important to characterize the alteration of vasomotor activity of the retinal 
circulation in early diabetes. Herein, I will discuss below on the alteration of retinal vascular 
reactivity in response to several endogenous vasoconstrictors mentioned earlier in this section 
and also focus on the venular responsiveness if the literature is available.  
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DR, diabetic retinopathy; DME, diabetes macular edema; IDDM, Insulin-dependent diabetes 
mellitus; NPDR, non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy; 
RBF, retinal blood flow; OCT, optical coherence tomography; FD-OCT, Fourier-domain optical 
coherence tomography. 
 
Involvement of Vasoconstrictors in the Pathogenesis of Diabetic Retinopathy 
             The ocular expression of several endogenous vasoconstrictors (ET-1, TXA2, 
angiotensin II, and norepinephrine) have been demonstrated in various animal models, 
including humans.  
 
ET-1 
             Accumulating evidence has shown that aqueous humor7, vitreous humor8 and plasma8 
levels of ET-1 are elevated in diabetes, especially in diabetic patients with proliferative diabetic 
retinopathy. It has been speculated that the elevated ET-1 is closely associated with the 
reduced retinal blood flow in patients with non-proliferative diabetic retinopathy.41,121,122 In 
cellular and molecular studies, high-glucose treatment increases permeability of endothelial 
cells through upregulated ET-1 expression, possibly through PKC isoform activation.123 
Activation of PKC-β and PKC-δ can enhance the expression of ET-1 with high-glucose in bovine 
retinal capillary endothelial cells and bovine retinal pericytes.124 In addition, the bovine retinal 
pericytes treated with a high concentration of glucose (25 mM) showed a reduction of ET-1-
stimulated Ca2+ influx from the L-type Ca2+ channels.125 However, it is unclear whether the 
endothelium and vascular smooth muscle are affected by the high glucose, and it remains 
unknow whether the vasomotor response of retinal venules to ET-1 is altered in early diabetes. 
In STZ-induced diabetic rats, intravitreal injection of ETAR or ETBR antagonist attenuated retinal 
inflammation and reduced retinal vascular leakage.126 The diabetes-dependent reduction of 
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retinal blood flow can be prevented by administration of an ETAR antagonist.110 These studies 
suggest the pathophysiological role of ET-1, as well as the involved ET receptors, in the 
development of diabetic retinopathy. Interestingly, intravitreal injection of ET-1 causes retinal 
arterial constriction and slows down the retinal circulation (i.e., increased flow resistance), which 
are both attenuated in the animals after induction of diabetes by STZ for one week.21 This in-
vivo study appears to suggest that the increase of blood flow and relaxation of retinal 
vasculature by ET-1 in diabetes, possibly due to desensitization of ET receptors in the vascular 
smooth muscle cells that are pre-exposed to the elevated level of endogenous ET-1 in 
diabetes.21 In retinal arterioles isolated from type I diabetic pigs, the endothelium-dependent 
NO-mediated vasodilator function was found to be compromised,127,128 but the ability of these 
diseased vessels to constrict to ET-1 was unaffected.128 It remains to be determined whether 
the vasomotor response of retinal venules to ET-1 is affected by diabetes. 
 
TXA2 
             The increased expression level of TXA2 in plasma or serum with diabetes mellitus has 
been shown in epidemiological and animal studies.9,49,129-132 Interestingly, the TXA2 and PGI2 
productions have been shown to link to the pathological development of diabetic 
retinopathy.133,134 Application of thromboxane receptor antagonist in mice attenuates diabetes-
induced retinal vasoconstriction without altering the retinal levels of thromboxane receptor and 
thromboxane synthase.111 Moreover, incubation of cultured bovine retinal endothelial cells with 
high levels of glucose increases the production of TXA2.130 Although the TXB2 (a stable TXA2 
metabolite) level is detectable in the human vitreous humor51 and the location of TXA2 receptor 
expression in human eyes has been identified,52 the information on the expression and function 





             Angiotensin II is implicated as one of the contributing factors in the vascular 
complication during diabetes.135 The elevated expression level of angiotensin II has been shown 
in the retinal tissue and vitreous humor of experimental models of diabetes,11,136 and in the 
vitreous humor of patients with proliferative diabetic retinopathy.137,138 ACE inhibition ameliorates 
diabetes-induced retinal hyperpermeability139 and abnormal oscillatory potential amplitudes of 
the electroretinogram.140 Moreover, application of ACE inhibition or angiotensin AT1 receptor 
antagonism in rats restores diabetes-induced attenuation of retinal blood flow.141 Although the 
angiotensin II level is detectable in the vitreous humor of human137,138 or experimental animal 
models,11,136 the information on vasomotor function of the retinal vasculature to angiotensin II 
during euglycemia or diabetes is limited. 
 
Norepinephrine 
             The α1-adrenergic and α2-adrenergic receptors are conventionally thought to mediate 
vasoconstriction in vascular system. Interestingly, elevation of serum levels of α- and β-
adrenergic receptors agonist norepinephrine (nanomolar level in normal plasma) has been 
documented in diabetic rats.10 In addition, activation of β-adrenergic signaling appears to 
decrease VEGF levels,142 and attenuate pericyte loss143 in the diabetic retina, suggesting the 
protective role of β-adrenergic activation in diabetic retinopathy. A previous study examining the 
retinal arterial reaction to an α2-adrenergic receptor agonist (brimonidine) showed dilation of 
large retinal arterioles (> 60 µm in diameter) but constriction of small retinal arterioles (< 60 µm 
in diameter).71 It appears that α-adrenergic activation might elicit heterogeneous vasomotor 
responses in the retinal vascular network. Although one study has showed a decreased 
systemic vasopressor response to norepinephrine in rats at 4 weeks of diabetes induced by 
STZ,144 it remains unclear whether diabetes has any impact on the vasomotor response of 
retinal venules to phenylephrine and norepinephrine stimulation.  
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Perspective on NCX-NHE Pathway  
             Cytosolic Ca2+, the important molecule for smooth muscle contraction, can be elevated 
via several pathways, including the transmembrane exchange mechanisms. The forward mode 
of NCX prevents Ca2+ overload of the cells by using energy, i.e., electrochemical influx of Na+ to 
counter transport of Ca2+ across the plasma membrane with 3 Na+ to 1 Ca2+ ratio.145 However, 
when intracellular levels of Na+ rise beyond a critical point, the reverse-mode NCX begins 
importing Ca2+.145 The biological roles of NCX have been demonstrated in various 
tissues/organs146-149 and its participation in the development of cardiovascular disease,150-152 
possibly related to hyperglycemia and vascular disorders as suggested recently.149,153-156 On the 
other hand, the impact of NCX on the vasculature is less understood. Szewczyk et al. have 
demonstrated mRNA and protein expressions of NCX1 in the endothelium and smooth muscle 
of porcine coronary arteries,157 but the functional role of NCX remains to be determined. A 
reverse-mode NCX inhibitor, KB-R7943, has been shown to inhibit ET-1-induced contractions of 
cardiac papillary muscle in cats and vena cava in rats.14 Takai et al. reported that KB-R7943 
inhibited the extracellular Na+-dependent change in Ca2+i in rat carotid arterial myocytes, which 
was presumably related to the reverse mode of NCX.158 Interestingly, a recent study 
demonstrated that the reverse-mode NCX is involved in intracellular Ca2+ mobilization and 
predominantly mediates ET-1-induced contraction of the rat vena cava.159 However, the 
possible effect of ET-1 in which Na+i mediates Ca2+ influx via reverse-mode NCX has not been 
examined in retinal venules under diabetic insults. Activation of vascular smooth muscle NCX1 
has been reported to be involved in the maintenance of blood pressure by using smooth 
muscle-specific knockout of NCX1,160 and in the initiation of salt-sensitive hypertension.161 
These studies suggest the critical role of NCX in maintaining vascular homeostasis and possibly 
contributing to vascular disorders by enhancing vasoconstriction. For example, the NCX 
inhibitor has been reported to protect endothelial function from hyperglycemic insults.153 
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However, little is known about the mechanism of regulating NCX-dependent constriction of 
retinal venules under hyperglycemic insults. 
             Namekata and colleagues have shown that ET-1-induced positive inotropy is mediated 
by NHE (Na+i-dependent) and that negative inotropy is related to the activity of NCX in mouse 
ventricular myocardium.162 This study suggests an interaction of NHE and NCX in regulating 
myocardial function. This context is supported by the involvement of PKC-dependent and NHE-
dependent activation of reverse-mode NCX in ET-1-induced positive inotropic effects of cat 
papillary muscles.14 Because NHE mediates the transmembrane exchange of one sodium for 
one hydrogen via the electrochemical gradient,163 the elevated cytosolic sodium by NHE can 
potentially activate reverse-mode NCX in the disease state, i.e., hyperglycemic insult, and 
consequently alter vascular reactivity to endogenous vasoconstrictors. This context is supported 
by the observed elevation of cytosolic Ca2+ by enhanced reverse-mode NCX activity after 
sodium overload, leading to a positive inotropic effect of cardiomyocytes (Figure 2)36 and 
smooth muscle cell contraction in response to ET-1.13 The contribution of NHE-NCX to disease 
development is also evident by the elevation of NHE mRNA in the diabetic retina 16 and in 
agonists-induced myocardial hypertrophy.164,165 Interestingly, p38 MAPK activity in mesangial 
cells, under ET-1 stimulation, was found to be enhanced under hyperglycemia.166 Because p38 
MAPK-dependent activation of NHE has also been demonstrated under ET-1 stimulation,167 the 
signaling from p38 MAPK may be important in modulating NHE-NCX activity in disease states. 
Moreover, inhibition of NHE activity has been shown to preserve coronary endothelial function168 
and reduce resistivity index of the central retinal artery in diabetic rats.16 It is likely that activation 



















Figure 2. Summary of signal transduction mechanisms involved in ET-1-mediated positive 
inotropic effects of cardiomyocytes (Figure modified from Brunner F, Brás-Silva C, Cerdeira 
AS, Leite-Moreira AF. Cardiovascular endothelins: essential regulators of cardiovascular 




             The venular vasculature is the most effective vessel segment in the circulation in terms 
of regulating capillary pressure and fluid homeostasis by altering its activity, i.e., constriction or 
dilation. However, the research of retinal venules in response to endogenous vasoconstrictors is 
sparse. In this dissertation, I characterized the vasomotor response of isolated porcine retinal 
venule to ET-1 and other vasoconstrictors (norepinephrine, phenylephrine, TXA2, and 
angiotensin II) with and without hyperglycemic/diabetic insults. I will pay special attention to the 
determination of signaling mechanisms (Figure 3) responsible for the vasoconstriction to ET-1 
(Chapter II) because this peptide has been consistently shown to be involved in the 
pathogenesis of diabetic retinopathy as discussed above. In the pig model of chronic 
hyperglycemia/diabetes (induced by STZ) and acute hyperglycemia (exposure of the vessel to a 
high level of glucose), I examined whether these insults can alter retinal venular responses to 
the aforementioned vasoconstrictors and determined whether activation of p38 MAPK and NHE-
NCX contribute to the observed retinal venular dysfunction (Chapter III). Furthermore, in order 
to support the porcine retinal venous vessels as a viable model resembling the human ocular 
microcirculation, I also investigated the vasomotor responses of human retinal venules to ET-1 
and norepinephrine (Chapter IV). My detailed investigations are described in the following 































1. Lutty GA. Effects of diabetes on the eye. Invest Ophthalmol Vis Sci. 2013;54:ORSF81-
ORSF87. 
2. Davis MJ, Hill MA, Kuo L. Local regulation of microvascular perfusion. In: Tuma RF, 
Duran WN, Ley K, eds. Handbook of Physiology: The Cardiovascular System, 
Microcirculation (Section 2). 2nd ed. San Diego, CA: Academic Press; 2008:161-284. 
3. Johnson PC. Overview of the microcirculation. In: Tuma RF, Duran WN, Ley K, eds. 
Handbook of Physiology: The Cardiovascular System, Microcirculation. 2nd ed. San 
Diego, CA: Academic Press; 2008:xi-xxiv. 
4. Cybulska-Heinrich AK, Baertschi M, Loesche CC, et al. Patients with diabetic retinopathy 
have high retinal venous pressure. EPMA J. 2015;6:5. 
5. Pechauer AD, Hwang TS, Hagag AM, et al. Assessing total retinal blood flow in diabetic 
retinopathy using multiplane en face Doppler optical coherence tomography. Br J 
Ophthalmol. 2018;102:126-130. 
6. Roldan-Pallares M, Rollin R, Mediero A, et al. Immunoreactive ET-1 in the vitreous 
humor and epiretinal membranes of patients with proliferative vitreoretinopathy. Mol Vis. 
2005;11:461-471. 
7. Khuu LA, Tayyari F, Sivak JM, et al. Aqueous humor endothelin-1 and total retinal blood 
flow in patients with non-proliferative diabetic retinopathy. Eye (Lond). 2017;31:1443-
1450. 
8. Roldan-Pallares M, Rollin R, Martinez-Montero JC, Fernandez-Cruz A, Bravo-Llata C, 
Fernandez-Durango R. Immunoreactive endothelin-1 in the vitreous humor and 
epiretinal membranes of patients with proliferative diabetic retinopathy. Retina. 
2007;27:222-235. 
 28 
9. De La Cruz JP, Moreno A, Ruiz-Ruiz MI, Sanchez De La Cuesta F. Effect of DT-TX 30, 
a combined thromboxane synthase inhibitor and thromboxane receptor antagonist, on 
retinal vascularity in experimental diabetes mellitus. Thromb Res. 2000;97:125-131. 
10. Paulson DJ, Light KE. Elevation of serum and ventricular norepinephrine content in the 
diabetic rat. Res Commun Chem Pathol Pharmacol. 1981;33:559-562. 
11. Nagai N, Izumi-Nagai K, Oike Y, et al. Suppression of diabetes-induced retinal 
inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear 
factor-kappaB pathway. Invest Ophthalmol Vis Sci. 2007;48:4342-4350. 
12. Berridge MJ. Smooth muscle cell calcium activation mechanisms. J Physiol. 
2008;586:5047-5061. 
13. Horinouchi T, Terada K, Higashi T, Miwa S. Endothelin receptor signaling: new insight 
into its regulatory mechanisms. J Pharmacol Sci. 2013;123:85-101. 
14. Aiello EA, Villa-Abrille MC, Dulce RA, Cingolani HE, Perez NG. Endothelin-1 stimulates 
the Na+/Ca2+ exchanger reverse mode through intracellular Na+ (Na+i)-dependent and 
Na+i-independent pathways. Hypertension. 2005;45:288-293. 
15. Nishio S, Teshima Y, Takahashi N, et al. Activation of CaMKII as a key regulator of 
reactive oxygen species production in diabetic rat heart. J Mol Cell Cardiol. 
2012;52:1103-1111. 
16. Cukiernik M, Hileeto D, Downey D, et al. The role of the sodium hydrogen exchanger-1 
in mediating diabetes-induced changes in the retina. Diabetes Metab Res Rev. 
2004;20:61-71. 
17. Pappenheimer JR, Soto-Rivera A. Effective osmotic pressure of the plasma proteins and 
other quantities associated with the capillary circulation in the hindlimbs of cats and 
dogs. Am J Physiol. 1948;152:471-491. 
18. Fraenkl SA, Mozaffarieh M, Flammer J. Retinal vein occlusions: the potential impact of a 
dysregulation of the retinal veins. EPMA J. 2010;1:253-261. 
 29 
19. Iannaccone A, Letizia C, Pazzaglia S, Vingolo EM, Clemente G, Pannarale MR. Plasma 
endothelin-1 concentrations in patients with retinal vein occlusions. Br J Ophthalmol. 
1998;82:498-503. 
20. Flammer J, Konieczka K. Retinal venous pressure: the role of endothelin. EPMA J. 
2015;6:21. 
21. Bursell SE, Clermont AC, Oren B, King GL. The in vivo effect of endothelins on retinal 
circulation in nondiabetic and diabetic rats. Invest Ophthalmol Vis Sci. 1995;36:596-607. 
22. Yoshida A, Feke GT, Morales-Stoppello J, Collas GD, Goger DG, McMeel JW. Retinal 
blood flow alterations during progression of diabetic retinopathy. Arch Ophthalmol. 
1983;101:225-227. 
23. Schneider JG, Tilly N, Hierl T, et al. Elevated plasma endothelin-1 levels in diabetes 
mellitus. Am J Hypertens. 2002;15:967-972. 
24. Oku H, Kida T, Sugiyama T, Hamada J, Sato B, Ikeda T. Possible involvement of 
endothelin-1 and nitric oxide in the pathogenesis of proliferative diabetic retinopathy. 
Retina. 2001;21:647-651. 
25. Kiel JW. The Ocular Circulation. 1st ed. San Rafael, CA: Morgan & Claypool Life 
Sciences; 2010:1-69. 
26. Yu DY, Su EN, Cringle SJ, Morgan WH, McAllister IL, Yu PK. Local modulation of retinal 
vein tone. Invest Ophthalmol Vis Sci. 2016;57:412-419. 
27. Barber AJ, Antonetti DA. Mapping the blood vessels with paracellular permeability in the 
retinas of diabetic rats. Invest Ophthalmol Vis Sci. 2003;44:5410-5416. 
28. Qaum T, Xu Q, Joussen AM, et al. VEGF-initiated blood-retinal barrier breakdown in 
early diabetes. Invest Ophthalmol Vis Sci. 2001;42:2408-2413. 
29. Klaassen I, Van Noorden CJ, Schlingemann RO. Molecular basis of the inner blood-
retinal barrier and its breakdown in diabetic macular edema and other pathological 
conditions. Prog Retin Eye Res. 2013;34:19-48. 
 30 
30. Tatara T. Context-sensitive fluid therapy in critical illness. J Intensive Care. 2016;4:20. 
31. Folkow B, Lundgren O, Wallentin I. Studies on the relationship between flow resistance, 
capillary filtration coefficient and regional blood volume in the intestine of the cat. Acta 
Physiol Scand. 1963;57:270-283. 
32. Johnson PC. Effect of venous pressure on mean capillary pressure and vascular 
resistance in the intestine. Circ Res. 1965;16:294-300. 
33. Rosa RH, Jr., Hein TW, Yuan Z, et al. Brimonidine evokes heterogeneous vasomotor 
response of retinal arterioles: diminished nitric oxide-mediated vasodilation when size 
goes small. Am J Physiol Heart Circ Physiol. 2006;291:H231-H238. 
34. Salvatore S, Vingolo EM. Endothelin-1 role in human eye: a review. J Ophthalmol. 
2010;2010:354645. 
35. Houde M, Desbiens L, D'Orleans-Juste P. Endothelin-1: biosynthesis, signaling and 
vasoreactivity. Adv Pharmacol. 2016;77:143-175. 
36. Brunner F, Bras-Silva C, Cerdeira AS, Leite-Moreira AF. Cardiovascular endothelins: 
essential regulators of cardiovascular homeostasis. Pharmacol Ther. 2006;111:508-531. 
37. Murphy JA, Archibald ML, Baldridge WH, Chauhan BC. Endothelin-1-induced 
proliferation is reduced and Ca2+ signaling is enhanced in endothelin B-deficient optic 
nerve head astrocytes. Invest Ophthalmol Vis Sci. 2011;52:7771-7777. 
38. Thengchaisri N, Hein TW, Ren Y, Kuo L. Endothelin-1 impairs coronary arteriolar 
dilation: role of p38 kinase-mediated superoxide production from NADPH oxidase. J Mol 
Cell Cardiol. 2015;86:75-84. 
39. Polak K, Luksch A, Frank B, Jandrasits K, Polska E, Schmetterer L. Regulation of 
human retinal blood flow by endothelin-1. Exp Eye Res. 2003;76:633-640. 
40. Chakravarthy U, Douglas AJ, Bailie JR, McKibben B, Archer DB. Immunoreactive 
endothelin distribution in ocular tissues. Invest Ophthalmol Vis Sci. 1994;35:2448-2454. 
 31 
41. Pang IH, Yorio T. Ocular actions of endothelins. Proc Soc Exp Biol Med. 1997;215:21-
34. 
42. Luksch A, Wimpissinger B, Polak K, Jandrasits K, Schmetterer L. ETA-receptor 
blockade, but not ACE inhibition, blunts retinal vessel response during isometric 
exercise. Am J Physiol Heart Circ Physiol. 2006;290:H1693-1698. 
43. Hein TW, Ren Y, Yuan Z, et al. Functional and molecular characterization of the 
endothelin system in retinal arterioles. Invest Ophthalmol Vis Sci. 2009;50:3329-3336. 
44. Potts LB, Ren Y, Lu G, et al. Constriction of retinal arterioles to endothelin-1: requisite 
role of Rho kinase independent of protein kinase C and L-type calcium channels. Invest 
Ophthalmol Vis Sci. 2012;53:2904-2912. 
45. Potts LB, Bradley PD, Xu W, Kuo L, Hein TW. Role of endothelium in vasomotor 
responses to endothelin system and protein kinase C activation in porcine retinal 
arterioles. Invest Ophthalmol Vis Sci. 2013;54:7587-7594. 
46. Hein TW, Rosa RH, Jr., Yuan Z, Roberts E, Kuo L. Divergent roles of nitric oxide and 
Rho kinase in vasomotor regulation of human retinal arterioles. Invest Ophthalmol Vis 
Sci. 2010;51:1583-1590. 
47. Bos CL, Richel DJ, Ritsema T, Peppelenbosch MP, Versteeg HH. Prostanoids and 
prostanoid receptors in signal transduction. Int J Biochem Cell Biol. 2004;36:1187-1205. 
48. Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc 
Biol. 2011;31:986-1000. 
49. Halushka PV, Rogers RC, Loadholt CB, et al. Increased platelet prostaglandin and 
thromboxane synthesis in diabetes mellitus. Horm Metab Res Suppl. 1981;11:7-11. 
50. Coleman RA, Humphrey PP, Kennedy I, Levy GP, Lumley P. Comparison of the actions 
of U46619, a prostaglandin H2-analogue, with those of prostaglandin H2 and 
thromboxane A2 on some isolated smooth muscle preparations. Br J Pharmacol. 
1981;73:773-778. 
 32 
51. Thomas MA, O'Grady GE, Swartz SL. Prostaglandin levels in human vitreous. Br J 
Ophthalmol. 1985;69:275-279. 
52. Chen Z, Prasad S, Cynader M. Localisation of thromboxane A2 receptors and the 
corresponding mRNAs in human eye tissue. Br J Ophthalmol. 1994;78:921-926. 
53. Abran D, Varma DR, Chemtob S. Regulation of prostanoid vasomotor effects and 
receptors in choroidal vessels of newborn pigs. Am J Physiol. 1997;272:R995-1001. 
54. Nielsen PJ, Nyborg NC. Contractile and relaxing effects of arachidonic acid derivatives 
on isolated bovine retinal resistance arteries. Exp Eye Res. 1990;50:305-311. 
55. Holmgaard K, Aalkjaer C, Lambert JD, Hessellund A, Bek T. The relaxing effect of 
perivascular tissue on porcine retinal arterioles in vitro is mimicked by N-methyl-D-
aspartate and is blocked by prostaglandin synthesis inhibition. Acta Ophthalmol. 
2008;86:26-33. 
56. Torring MS, Aalkjaer C, Bek T. Constriction of porcine retinal arterioles induced by 
endothelin-1 and the thromboxane analogue U46619 in vitro decreases with increasing 
vascular branching level. Acta Ophthalmol. 2014;92:232-237. 
57. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol 
Rev. 2006;86:747-803. 
58. Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological 
and pathophysiological actions of angiotensin II in vascular smooth muscle cells. 
Pharmacol Rev. 2000;52:639-672. 
59. Danser AH, Derkx FH, Admiraal PJ, Deinum J, de Jong PT, Schalekamp MA. 
Angiotensin levels in the eye. Invest Ophthalmol Vis Sci. 1994;35:1008-1018. 
60. Schonfelder U, Hofer A, Paul M, Funk RH. In situ observation of living pericytes in rat 
retinal capillaries. Microvasc Res. 1998;56:22-29. 
61. Kawamura H, Kobayashi M, Li Q, et al. Effects of angiotensin II on the pericyte-
containing microvasculature of the rat retina. J Physiol. 2004;561:671-683. 
 33 
62. Zhang T, Wu DM, Xu GZ, Puro DG. The electrotonic architecture of the retinal 
microvasculature: modulation by angiotensin II. J Physiol. 2011;589:2383-2399. 
63. Rockwood EJ, Fantes F, Davis EB, Anderson DR. The response of retinal vasculature to 
angiotensin. Invest Ophthalmol Vis Sci. 1987;28:676-682. 
64. Nyborg NC, Nielsen PJ, Prieto D, Benedito S. Angiotensin II does not contract bovine 
retinal resistance arteries in vitro. Exp Eye Res. 1990;50:469-474. 
65. Kulkarni PS, Hamid H, Barati M, Butulija D. Angiotensin II-induced constrictions are 
masked by bovine retinal vessels. Invest Ophthalmol Vis Sci. 1999;40:721-728. 
66. Eisenhofer G, Kopin IJ, Goldstein DS. Catecholamine metabolism: a contemporary view 
with implications for physiology and medicine. Pharmacol Rev. 2004;56:331-349. 
67. Flatmark T. Catecholamine biosynthesis and physiological regulation in neuroendocrine 
cells. Acta Physiol Scand. 2000;168:1-17. 
68. Hervet T, Teresinski G, Hejna P, Descloux E, Grouzmann E, Palmiere C. 
Catecholamines and their O-methylated metabolites in vitreous humor in hypothermia 
cases. Forensic Sci Med Pathol. 2016;12:163-169. 
69. Wilke N, Janssen H, Fahrenhorst C, et al. Postmortem determination of concentrations 
of stress hormones in various body fluids--is there a dependency between 
adrenaline/noradrenaline quotient, cause of death and agony time? Int J Legal Med. 
2007;121:385-394. 
70. Bylund DB, Chacko DM. Characterization of α2 adrenergic receptor subtypes in human 
ocular tissue homogenates. Invest Ophthalmol Vis Sci. 1999;40:2299-2306. 
71. Rosa RH, Jr., Hein TW, Yuan Z, et al. Brimonidine evokes heterogeneous vasomotor 
response of retinal arterioles: diminished nitric oxide-mediated vasodilation when size 
goes small. Am J Physiol Heart Circ Physiol. 2006;291:H231-238. 
 34 
72. Ehinger B, Falck B. Morphological and pharmacohistochemical characteristics of 
adrenergic retinal neurons of some mammals. Albrecht Von Graefes Arch Klin Exp 
Ophthalmol. 1969;178:295-305. 
73. McAuliffe-Curtin D, Buckley C. Review of α adrenoceptor function in the eye. Eye (Lond). 
1989;3:472-476. 
74. Bohmer T, Manicam C, Steege A, Michel MC, Pfeiffer N, Gericke A. The α2B-
adrenoceptor subtype mediates adrenergic vasoconstriction in mouse retinal arterioles 
with damaged endothelium. Br J Pharmacol. 2014;171:3858-3867. 
75. Forster BA, Ferrari-Dileo G, Anderson DR. Adrenergic α1 and α2 binding sites are 
present in bovine retinal blood vessels. Invest Ophthalmol Vis Sci. 1987;28:1741-1746. 
76. Josefsson A, Sigurdsson SB, Bang K, Eysteinsson T. Dorzolamide induces 
vasodilatation in isolated pre-contracted bovine retinal arteries. Exp Eye Res. 
2004;78:215-221. 
77. Yu DY, Alder VA, Cringle SJ, Su EN, Yu PK. Vasoactivity of intraluminal and 
extraluminal agonists in perfused retinal arteries. Invest Ophthalmol Vis Sci. 
1994;35:4087-4099. 
78. Hara H, Ichikawa M, Oku H, Shimazawa M, Araie M. Bunazosin, a selective α1-
adrenoceptor antagonist, as an anti-glaucoma drug: effects on ocular circulation and 
retinal neuronal damage. Cardiovasc Drug Rev. 2005;23:43-56. 
79. Ferrari-Dileo G, Davis EB, Anderson DR. Response of retinal vasculature to 
phenylephrine. Invest Ophthalmol Vis Sci. 1990;31:1181-1182. 
80. Hoste AM, Boels PJ, Brutsaert DL, De Laey JJ. Effect of α1 and β agonists on 
contraction of bovine retinal resistance arteries in vitro. Invest Ophthalmol Vis Sci. 
1989;30:44-50. 
81. Cheng J, Yu J, Jiang C, Sun X. Phenylephrine affects peripapillary retinal vasculature-an 
optic coherence tomography angiography study. Front Physiol. 2017;8:996. 
 35 
82. Takayama J, Mishima A, Ishii K. Effects of topical phenylephrine on blood flow in the 
posterior segments of monkey and aged human eyes. Jpn J Ophthalmol. 2004;48:243-
248. 
83. Puetz S, Lubomirov LT, Pfitzer G. Regulation of smooth muscle contraction by small 
GTPases. Physiology (Bethesda). 2009;24:342-356. 
84. Stewart M, Needham M, Bankhead P, et al. Feedback via Ca2+-activated ion channels 
modulates endothelin 1 signaling in retinal arteriolar smooth muscle. Invest Ophthalmol 
Vis Sci. 2012;53:3059-3066. 
85. Miwa S, Iwamuro Y, Zhang XF, et al. Ca2+ entry channels in rat thoracic aortic smooth 
muscle cells activated by endothelin-1. Jpn J Pharmacol. 1999;80:281-288. 
86. Kawanabe Y, Hashimoto N, Masaki T. Characterization of Ca2+ channels involved in 
endothelin-1-induced contraction of rabbit basilar artery. J Cardiovasc Pharmacol. 
2002;40:438-447. 
87. Reading SA, Earley S, Waldron BJ, Welsh DG, Brayden JE. TRPC3 mediates pyrimidine 
receptor-induced depolarization of cerebral arteries. Am J Physiol Heart Circ Physiol. 
2005;288:H2055-H2061. 
88. Onohara N, Nishida M, Inoue R, et al. TRPC3 and TRPC6 are essential for angiotensin 
II-induced cardiac hypertrophy. EMBO J. 2006;25:5305-5316. 
89. Lemos VS, Poburko D, Liao CH, Cole WC, van Breemen C. Na+ entry via TRPC6 
causes Ca2+ entry via NCX reversal in ATP stimulated smooth muscle cells. Biochem 
Biophys Res Commun. 2007;352:130-134. 
90. Eder P, Probst D, Rosker C, et al. Phospholipase C-dependent control of cardiac 
calcium homeostasis involves a TRPC3-NCX1 signaling complex. Cardiovasc Res. 
2007;73:111-119. 
 36 
91. Chik CL, Li B, Ogiwara T, Ho AK, Karpinski E. PACAP modulates L-type Ca2+ channel 
currents in vascular smooth muscle cells: involvement of PKC and PKA. FASEB J. 
1996;10:1310-1317. 
92. Obejero-Paz CA, Auslender M, Scarpa A. PKC activity modulates availability and long 
openings of L-type Ca2+ channels in A7r5 cells. Am J Physiol. 1998;275:C535-543. 
93. Viard P, Exner T, Maier U, Mironneau J, Nurnberg B, Macrez N. Gbetagamma dimers 
stimulate vascular L-type Ca2+ channels via phosphoinositide 3-kinase. FASEB J. 
1999;13:685-694. 
94. Ren C, Zhang J, Philipson KD, Kotlikoff MI, Blaustein MP, Matteson DR. Activation of L-
type Ca2+ channels by protein kinase C is reduced in smooth muscle-specific Na+/Ca2+ 
exchanger knockout mice. Am J Physiol Heart Circ Physiol. 2010;298:H1484-1491. 
95. Hirata T, Ushikubi F, Kakizuka A, Okuma M, Narumiya S. Two thromboxane A2 receptor 
isoforms in human platelets. Opposite coupling to adenylyl cyclase with different 
sensitivity to Arg60 to Leu mutation. J Clin Invest. 1996;97:949-956. 
96. Miggin SM, Kinsella BT. Expression and tissue distribution of the mRNAs encoding the 
human thromboxane A2 receptor (TP) alpha and beta isoforms. Biochim Biophys Acta. 
1998;1425:543-559. 
97. Shenker A, Goldsmith P, Unson CG, Spiegel AM. The G protein coupled to the 
thromboxane A2 receptor in human platelets is a member of the novel Gq family. Trans 
Assoc Am Physicians. 1991;104:11-20. 
98. Chen H. Role of thromboxane A2 signaling in endothelium-dependent contractions of 
arteries. Prostaglandins Other Lipid Mediat. 2018;134:32-37. 
99. Tosun M, Paul RJ, Rapoport RM. Role of extracellular Ca2+ influx via L-type and non-L-
type Ca2+ channels in thromboxane A2 receptor-mediated contraction in rat aorta. J 
Pharmacol Exp Ther. 1998;284:921-928. 
 37 
100. Kulkarni P, Payne S. Eicosanoids in bovine retinal microcirculation. J Ocul Pharmacol 
Ther. 1997;13:139-149. 
101. Spada CS, Nieves AL, Woodward DF. Vascular activities of prostaglandins and selective 
prostanoid receptor agonists in human retinal microvessels. Exp Eye Res. 2002;75:155-
163. 
102. Fletcher EL, Phipps JA, Ward MM, Vessey KA, Wilkinson-Berka JL. The renin-
angiotensin system in retinal health and disease: its influence on neurons, glia and the 
vasculature. Prog Retin Eye Res. 2010;29:284-311. 
103. Kimura K, Eguchi S. Angiotensin II type-1 receptor regulates RhoA and Rho-
kinase/ROCK activation via multiple mechanisms. Focus on "Angiotensin II induces 
RhoA activation through SHP2-dependent dephosphorylation of the RhoGAP p190A in 
vascular smooth muscle cells". Am J Physiol Cell Physiol. 2009;297:C1059-1061. 
104. Arun KH, Kaul CL, Ramarao P. AT1 receptors and L-type calcium channels: functional 
coupling in supersensitivity to angiotensin II in diabetic rats. Cardiovasc Res. 
2005;65:374-386. 
105. Finch AM, Sarramegna V, Graham RM. Ligand binding, activation, and agonist 
trafficking. In: Perez DM, ed. The Adrenergic Receptors: In the 21ST Century. Totowa, 
NJ: Humana Press; 2006:25-86. 
106. Feke GT, Pasquale LR. Retinal blood flow response to posture change in glaucoma 
patients compared with healthy subjects. Ophthalmology. 2008;115:246-252. 
107. Lee B, Novais EA, Waheed NK, et al. En face Doppler optical coherence tomography 
measurement of total retinal blood flow in diabetic retinopathy and diabetic macular 
edema. JAMA Ophthalmol. 2017;135:244-251. 
108. Srinivas S, Tan O, Nittala MG, et al. Assessment of retinal blood flow in diabetic 
retinopathy using Doppler fourier-domain optical coherence tomography. Retina. 
2017;37:2001-2007. 
 38 
109. Wong TY, Cheung CM, Larsen M, Sharma S, Simo R. Diabetic retinopathy. Nat Rev Dis 
Primers. 2016;2:16012. 
110. Wang Z, Yadav AS, Leskova W, Harris NR. Attenuation of streptozotocin-induced 
microvascular changes in the mouse retina with the endothelin receptor A antagonist 
atrasentan. Exp Eye Res. 2010;91:670-675. 
111. Wright WS, Messina JE, Harris NR. Attenuation of diabetes-induced retinal 
vasoconstriction by a thromboxane receptor antagonist. Exp Eye Res. 2009;88:106-112. 
112. Grunwald JE, Riva CE, Brucker AJ, Sinclair SH, Petrig BL. Altered retinal vascular 
response to 100% oxygen breathing in diabetes mellitus. Ophthalmology. 1984;91:1447-
1452. 
113. Patel V, Rassam S, Newsom R, Wiek J, Kohner E. Retinal blood flow in diabetic 
retinopathy. BMJ. 1992;305:678-683. 
114. Bursell SE, Clermont AC, Kinsley BT, Simonson DC, Aiello LM, Wolpert HA. Retinal 
blood flow changes in patients with insulin-dependent diabetes mellitus and no diabetic 
retinopathy. Invest Ophthalmol Vis Sci. 1996;37:886-897. 
115. Konno S, Feke GT, Yoshida A, Fujio N, Goger DG, Buzney SM. Retinal blood flow 
changes in type I diabetes. A long-term follow-up study. Invest Ophthalmol Vis Sci. 
1996;37:1140-1148. 
116. Nagaoka T, Sato E, Takahashi A, Yokota H, Sogawa K, Yoshida A. Impaired retinal 
circulation in patients with type 2 diabetes mellitus: retinal laser Doppler velocimetry 
study. Invest Ophthalmol Vis Sci. 2010;51:6729-6734. 
117. Roy MS, Klein R, Janal MN. Retinal venular diameter as an early indicator of 
progression to proliferative diabetic retinopathy with and without high-risk characteristics 
in African Americans with type 1 diabetes mellitus. Arch Ophthalmol. 2011;129:8-15. 
 39 
118. Klein R, Myers CE, Lee KE, Gangnon R, Klein BE. Changes in retinal vessel diameter 
and incidence and progression of diabetic retinopathy. Arch Ophthalmol. 2012;130:749-
755. 
119. Frydkjaer-Olsen U, Soegaard Hansen R, Simo R, et al. Correlation between retinal 
vessel calibre and neurodegeneration in patients with type 2 diabetes mellitus in the 
european consortium for the early treatment of diabetic retinopathy (eurocondor). 
Ophthalmic Res. 2016;56:10-16. 
120. Nguyen HT, van Duinkerken E, Verbraak FD, et al. Retinal blood flow is increased in 
type 1 diabetes mellitus patients with advanced stages of retinopathy. BMC Endocr 
Disord. 2016;16:25. 
121. Takagi C, Bursell SE, Lin YW, et al. Regulation of retinal hemodynamics in diabetic rats 
by increased expression and action of endothelin-1. Invest Ophthalmol Vis Sci. 
1996;37:2504-2518. 
122. Granstam E, Wang L, Bill A. Ocular effects of endothelin-1 in the cat. Curr Eye Res. 
1992;11:325-332. 
123. Chen S, Apostolova MD, Cherian MG, Chakrabarti S. Interaction of endothelin-1 with 
vasoactive factors in mediating glucose-induced increased permeability in endothelial 
cells. Lab Invest. 2000;80:1311-1321. 
124. Park JY, Takahara N, Gabriele A, et al. Induction of endothelin-1 expression by glucose: 
an effect of protein kinase C activation. Diabetes. 2000;49:1239-1248. 
125. McGinty A, Scholfield CN, Liu WH, Anderson P, Hoey DE, Trimble ER. Effect of glucose 
on endothelin-1-induced calcium transients in cultured bovine retinal pericytes. J Biol 
Chem. 1999;274:25250-25253. 
126. Alrashdi SF, Deliyanti D, Wilkinson-Berka JL. Intravitreal administration of endothelin 
type A receptor or endothelin type B receptor antagonists attenuates hypertensive and 
diabetic retinopathy in rats. Exp Eye Res. 2018;176:1-9. 
 40 
127. Hein TW, Xu W, Xu X, Kuo L. Acute and chronic hyperglycemia elicit JIP1/JNK-mediated 
endothelial vasodilator dysfunction of retinal arterioles. Invest Ophthalmol Vis Sci. 
2016;57:4333-4340. 
128. Hein TW, Potts LB, Xu W, Yuen JZ, Kuo L. Temporal development of retinal arteriolar 
endothelial dysfunction in porcine type 1 diabetes. Invest Ophthalmol Vis Sci. 
2012;53:7943-7949. 
129. Moreno A, De La Cruz JP, Garcia Campos J, Sanchez De La Cuesta F. Prostacyclin-
thromboxane balance and retinal vascular pattern in rats with experimentally induced 
diabetes. Can J Ophthalmol. 1995;30:117-123. 
130. Sone H, Okuda Y, Kawakami Y, Yamashita K. Effects of high glucose concentration and 
a thromboxane synthase inhibitor on the production of thromboxane A2 and 
prostaglandin I2 and E2 by retinal endothelial cells. Life Sci. 1996;58:239-243. 
131. Hishinuma T, Tsukamoto H, Suzuki K, Mizugaki M. Relationship between 
thromboxane/prostacyclin ratio and diabetic vascular complications. Prostaglandins 
Leukot Essent Fatty Acids. 2001;65:191-196. 
132. Thomas G, Skrinska V, Lucas FV, Schumacher OP. Platelet glutathione and 
thromboxane synthesis in diabetes. Diabetes. 1985;34:951-954. 
133. Naveh-Floman N, Moisseiev J. Prostanoids and thromboxane A2 involvement in diabetic 
retinopathy. Metab Pediatr Syst Ophthalmol. 1982;6:321-325. 
134. Lane LS, Jansen PD, Lahav M, Rudy C. Circulating prostacyclin and thromboxane levels 
in patients with diabetic retinopathy. Ophthalmology. 1982;89:763-766. 
135. Schoonmaker GC, Fallet RW, Carmines PK. Superoxide anion curbs nitric oxide 
modulation of afferent arteriolar ANG II responsiveness in diabetes mellitus. Am J 
Physiol Renal Physiol. 2000;278:F302-309. 
136. Byon IS, Lee DH, Jun ES, Shin MK, Park SW, Lee JE. Effect of angiotensin II type 1 
receptor blocker and angiotensin converting enzyme inhibitor on the intraocular growth 
 41 
factors and their receptors in streptozotocin-induced diabetic rats. Int J Ophthalmol. 
2017;10:896-901. 
137. Funatsu H, Yamashita H, Nakanishi Y, Hori S. Angiotensin II and vascular endothelial 
growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Br J 
Ophthalmol. 2002;86:311-315. 
138. Funatsu H, Yamashita H, Noma H, Mimura T, Sakata K, Hori S. Risk evaluation of 
outcome of vitreous surgery for proliferative diabetic retinopathy based on vitreous level 
of vascular endothelial growth factor and angiotensin II. Br J Ophthalmol. 2004;88:1064-
1068. 
139. Gilbert RE, Kelly DJ, Cox AJ, et al. Angiotensin converting enzyme inhibition reduces 
retinal overexpression of vascular endothelial growth factor and hyperpermeability in 
experimental diabetes. Diabetologia. 2000;43:1360-1367. 
140. Bui BV, Armitage JA, Tolcos M, Cooper ME, Vingrys AJ. ACE inhibition salvages the 
visual loss caused by diabetes. Diabetologia. 2003;46:401-408. 
141. Horio N, Clermont AC, Abiko A, et al. Angiotensin AT1 receptor antagonism normalizes 
retinal blood flow and acetylcholine-induced vasodilatation in normotensive diabetic rats. 
Diabetologia. 2004;47:113-123. 
142. Jiang Y, Zhang Q, Steinle JJ. β-adrenergic receptor agonist decreases VEGF levels 
through altered eNOS and PKC signaling in diabetic retina. Growth Factors. 
2015;33:192-199. 
143. Yun JH, Jeong HS, Kim KJ, et al. β-adrenergic receptor agonists attenuate pericyte loss 
in diabetic retinas through Akt activation. FASEB J. 2018;32:2324-2338. 
144. Hong E, Huang F, Villafana S. Effect of early diabetes on the response to 
norepinephrine and dopamine in pithed Wistar Kyoto and spontaneously hypertensive 
rats. Clin Exp Hypertens. 2010;32:390-394. 
 42 
145. Khananshvili D. Sodium-calcium exchangers (NCX): molecular hallmarks underlying the 
tissue-specific and systemic functions. Pflugers Arch. 2014;466:43-60. 
146. Shattock MJ, Ottolia M, Bers DM, et al. Na+/Ca2+ exchange and Na+/K+-ATPase in the 
heart. J Physiol. 2015;593:1361-1382. 
147. Liao QS, Du Q, Lou J, Xu JY, Xie R. Roles of Na+/Ca2+ exchanger 1 in digestive system 
physiology and pathophysiology. World J Gastroenterol. 2019;25:287-299. 
148. Shenoda B. The role of Na+/Ca2+ exchanger subtypes in neuronal ischemic injury. Transl 
Stroke Res. 2015;6:181-190. 
149. Khananshvili D. The SLC8 gene family of sodium-calcium exchangers (NCX) - structure, 
function, and regulation in health and disease. Mol Aspects Med. 2013;34:220-235. 
150. Iwamoto T. Sodium-calcium exchange inhibitors: therapeutic potential in cardiovascular 
diseases. Future Cardiol. 2005;1:519-529. 
151. Pignataro G, Sirabella R, Anzilotti S, Di Renzo G, Annunziato L. Does Na+/Ca2+ 
exchanger, NCX, represent a new druggable target in stroke intervention? Transl Stroke 
Res. 2014;5:145-155. 
152. Ottolia M, Torres N, Bridge JH, Philipson KD, Goldhaber JI. Na/Ca exchange and 
contraction of the heart. J Mol Cell Cardiol. 2013;61:28-33. 
153. Liu D, Cui KZ, Sun YM, Liu JW, Li YB, Su Y. Protective effects of the sodium/calcium 
exchanger inhibitor on endothelial dysfunction induced by high glucose. Exp Clin 
Endocrinol Diabetes. 2015;123:7-10. 
154. Fernandez-Velasco M, Ruiz-Hurtado G, Gomez AM, Rueda A. Ca2+ handling alterations 
and vascular dysfunction in diabetes. Cell Calcium. 2014;56:397-407. 
155. Singh RM, Waqar T, Howarth FC, Adeghate E, Bidasee K, Singh J. Hyperglycemia-
induced cardiac contractile dysfunction in the diabetic heart. Heart Fail Rev. 2018;23:37-
54. 
 43 
156. Cui KZ, Liu D, Liu JW, et al. Role of the Na+/Ca2+ exchanger on the development of 
diabetes mellitus and its chronic complications. Biochem Biophys Res Commun. 
2012;426:445-447. 
157. Szewczyk MM, Davis KA, Samson SE, Simpson F, Rangachari PK, Grover AK. Ca2+-
pumps and Na+-Ca2+-exchangers in coronary artery endothelium versus smooth muscle. 
J Cell Mol Med. 2007;11:129-138. 
158. Takai N, Yamada A, Muraki K, Watanabe M, Imaizumi Y. KB-R7943 reveals possible 
involvement of Na+-Ca2+ exchanger in elevation of intracellular Ca2+ in rat carotid arterial 
myocytes. J Smooth Muscle Res. 2004;40:35-42. 
159. Tykocki NR, Jackson WF, Watts SW. Reverse-mode Na+/Ca2+ exchange is an important 
mediator of venous contraction. Pharmacol Res. 2012;66:544-554. 
160. Zhang J, Ren C, Chen L, et al. Knockout of Na+/Ca2+ exchanger in smooth muscle 
attenuates vasoconstriction and L-type Ca2+ channel current and lowers blood pressure. 
Am J Physiol Heart Circ Physiol. 2010;298:H1472-1483. 
161. Iwamoto T, Kita S, Zhang J, et al. Salt-sensitive hypertension is triggered by Ca2+ entry 
via Na+/Ca2+ exchanger type-1 in vascular smooth muscle. Nat Med. 2004;10:1193-
1199. 
162. Namekata I, Fujiki S, Kawakami Y, et al. Intracellular mechanisms and receptor types for 
endothelin-1-induced positive and negative inotropy in mouse ventricular myocardium. 
Naunyn Schmiedebergs Arch Pharmacol. 2008;376:385-395. 
163. Slepkov ER, Rainey JK, Sykes BD, Fliegel L. Structural and functional analysis of the 
Na+/H+ exchanger. Biochem J. 2007;401:623-633. 
164. Karmazyn M, Kilic A, Javadov S. The role of NHE-1 in myocardial hypertrophy and 
remodelling. J Mol Cell Cardiol. 2008;44:647-653. 
165. Stanbouly S, Kirshenbaum LA, Jones DL, Karmazyn M. Sodium hydrogen exchange 1 
(NHE-1) regulates connexin 43 expression in cardiomyocytes via reverse mode sodium 
 44 
calcium exchange and c-Jun NH2-terminal kinase-dependent pathways. J Pharmacol 
Exp Ther. 2008;327:105-113. 
166. Tsiani E, Lekas P, Fantus IG, Dlugosz J, Whiteside C. High glucose-enhanced activation 
of mesangial cell p38 MAPK by ET-1, ANG II, and platelet-derived growth factor. Am J 
Physiol Endocrinol Metab. 2002;282:E161-169. 
167. Horinouchi T, Asano H, Higa T, et al. Differential coupling of human endothelin type A 
receptor to Gq/11 and G12 proteins: the functional significance of receptor expression level 
in generating multiple receptor signaling. J Pharmacol Sci. 2009;111:338-351. 
168. Vial G, Dubouchaud H, Couturier K, Lanson M, Leverve X, Demaison L. Na+/H+ 
exchange inhibition with cariporide prevents alterations of coronary endothelial function 














II. CONSTRICTION OF RETINAL VENULES TO ENDOTHELIN-1: 
OBLIGATORY ROLES OF ETA RECEPTORS, EXTRACELLULAR 
CALCIUM ENTRY, AND RHO KINASE * 
 
Introduction 
             The light-sensitive retinal tissue exhibits a high metabolic rate, which requires the retinal 
circulation to provide sufficient oxygen and nutrients to maintain its proper function.15 In the 
microcirculation, two factors that impact optimal tissue perfusion are the arteriolar resistance for 
controlling blood flow and the venular resistance for regulating hydrostatic pressure and fluid 
homeostasis at the level of the capillaries.16,17 Because the retinal circulation lacks autonomic 
innervation,131 local vascular control mechanisms appear to dominate the regulation of retinal 
vascular resistance.132 Although the importance of the intrinsic ability of retinal arterioles to 
regulate their resting diameter is well established,132 there is paucity of information on 
vasomotor function of retinal venules. In vivo studies have reported an increase in retinal 
venular diameter during flickering light stimulation133 or a reduction in retinal venular diameter in 
response to hyperoxia,134 suggesting these vessels play an active role in flow regulation. 
However, it is difficult to distinguish the direct influence on retinal venular tone from a response 
secondary to the upstream changes in pressure and/or flow135 using a whole-organ approach or 
during systemic intervention. A recent report has shown that isolated porcine retinal veins are 
reactive to local vasoactive factors such as vasodilator adenosine and vasoconstrictor 
endothelin-1 (ET-1).18 It is unclear, however, whether smaller upstream venules exhibit similar 
                                               
* Reprinted with permission from “Constriction of retinal venules to endothelin-1: obligatory roles 
of ETA receptors, extracellular calcium entry, and Rho kinase” by Yen-Lin Chen, 2018. Invest 
Ophthalmol Vis Sci., 59, 5167-5175, Copyright [2018] by Yen-Lin Chen. 
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reactivity, especially vasoconstriction, which dictates not only blood drainage but also capillary 
pressure and fluid exchange.  
             ET-1 is a potent vasoactive peptide comprised of 21 amino acids and plays important 
roles in many biological functions, including vasoconstriction, cardiovascular remodeling, tissue 
inflammation, and cell proliferation.22-27,136,137 In the eye, ET-1 is distributed locally in the 
retina,31,138 causes retinal vasoconstriction in vivo,3,32,33,88 and reduces retinal blood flow.32,100,101 
Our previous studies have demonstrated the cell signaling mechanisms contributing to ET-1-
induced constriction of porcine and human retinal arterioles.28,29,34,35 Although others have 
shown that isolated porcine retinal veins are capable of constricting to ET-1,18 the underlying 
mechanisms contributing to this response have not been established. Accumulating evidence 
has shown that vitreous humor, plasma and ocular levels of ET-1 are elevated in 
diabetes,2,32,99,100 especially in patients with diabetic retinopathy.2,139 The increased plasma ET-1 
level also has been implicated in the pathogenesis of retinal vein occlusion (RVO).11,12 Because 
alteration in function of the retinal microcirculation, including tissue edema, is regarded as a key 
event contributing to visual impairment and blindness with diabetes and RVO, greater insight 
into the mechanisms controlling retinal venular vasomotor activity would advance our 
understanding of these retinal pathologies. 
             Previous studies in different organ systems and vascular beds have suggested that 
vasoconstriction to ET-1 can be mediated by the activation of its receptors (ETA and/or 
ETB),23,24,28 elevation of intracellular Ca2+,29,30,69,70 and signaling through Rho kinase (ROCK) 
and/or protein kinase C (PKC).23,29,68 However, the contributions of specific ET-1 receptors, 
extracellular Ca2+ entry, and intracellular signaling pathways to ET-1-induced constriction of 
retinal venules remain unknown. To address these issues directly without the influence of 
metabolic, hemodynamic and neuronal/glial factors commonly inherent in in vivo preparations, 
porcine retinal venules were isolated and pressurized for in vitro study. The relative functional 
roles of ETARs, ETBRs, ROCK, PKC, and extracellular Ca2+ entry through L-type voltage-
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operated Ca2+ channels (L-VOCCs) in the ET-1-induced constriction of porcine retinal venules 
were investigated. We also assessed ETAR, ETBR, and ROCK isoform (ROCK 1 and ROCK2) 




             All animal procedures were performed in accordance with the ARVO Statement for the 
Use of Animals in Ophthalmic and Vision Research and were approved by the Baylor Scott and 
White Health Institutional Animal Care and Use Committee. Pigs (Sus scrofa domesticus, 
Yorkshire) of either sex (age range, 8-12 weeks; weight range, 10-20 kg) purchased from Real 
Farms (San Antonio, TX, USA) were sedated with Telazol (4-8 mg/kg, intramuscularly), 
anesthetized with 2% to 5% isoflurane, and intubated. The procedure used for harvesting eyes 
has been described previously.140,141 
Isolation and Cannulation of Retinal Venules 
             We previously described the techniques for isolating and cannulating porcine retinal 
arterioles, which were applied to retinal venules in the current study.140-142 The ocular tissue was 
placed in a cooled dissection chamber (~8°C) containing a physiological salt solution (PSS; 
145.0 mM NaCl, 4.7 mM KCl, 2.0 mM CaCl2, 1.17 mM MgSO4, 1.2 mM NaH2PO4, 5.0 mM 
glucose, 2.0 mM pyruvate, 0.02 mM EDTA, and 3.0 mM MOPS) with 0.1% albumin. The retinal 
venules (1 to 1.5 mm in length without side branches) were identified based on the dark-red 
deoxygenated blood in the lumen and their thin vascular wall compared with the parallel 
arterioles containing bright-red oxygenated blood and a thick vascular wall. The second-order 
venules were carefully dissected with the aid of a stereomicroscope (model SZX12; Olympus, 
Melville, NY, USA). After removal of any remaining neural/connective tissues, the venule was 
transferred with a pipette to a polymethylmethacrylate vessel chamber containing PSS-albumin 
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solution equilibrated with room air at ambient temperature. Both ends of the venule were 
cannulated using glass micropipettes filled with PSS containing 1% albumin, and the outside of 
the venules were securely tied to the pipettes with 11-0 ophthalmic suture (Alcon, Fort Worth, 
TX, USA). Vessels were pressurized to 5 cmH2O (4 mmHg) intraluminal pressure by two 
independent pressure reservoirs and allowed to develop basal tone before study. This 
intraluminal pressure was chosen based on a study reporting porcine retinal transmural venous 
pressure of 0 to 4 mmHg.143 Vasomotor activity of isolated venules was recorded using 
videomicroscopic techniques throughout the experiments.140 
Experimental Protocols 
             Cannulated venules were bathed in PSS-albumin at 36° to 37°C to allow development 
(~90 minutes) of basal tone. In one series of studies, the vasomotor response to cumulative 
administration of ET-1 (1 pM to 10 nM; Bachem, Torrance, CA),28 selective ETBR agonist 
sarafotoxin S6c (10 pM to 0.1 µM; Tocris Cookson, Ellisville, MO),28 or PKC activator phorbol-
12,13-dibutyrate (PDBu; 0.1 µM to 10 µM)29 was evaluated. Retinal venules were exposed to 
each concentration of ET-1, sarafotoxin, or PDBu for 10 minutes until a stable diameter was 
established. Because the vasoconstrictor action of ET-1 was maintained after washout, only one 
concentration-response curve was constructed in each vessel for this drug. The relative roles of 
ETA receptors (ETARs) and ETB receptors (ETBRs) in the retinal venule responses to ET-1 were 
evaluated after treatment of the vessel with respective antagonists BQ123 (1 μM)28 and BQ788 
(0.1 μM).28 To assess the contribution of extracellular Ca2+ entry to ET-1-induced 
vasoconstriction, vasomotor activity was examined in Ca2+-free PSS-albumin (with 1 mM 
EDTA).26 The role of L-VOCCs in ET-1-induced vasoconstriction was examined in the presence 
of L-type Ca2+ channel antagonist nifedipine (1 μM).29,70 In another set of vessels, the specificity 
and efficacy of nifedipine were assessed by examining its effectiveness on vasoconstriction to 
L-VOCC activator Bay K8644 (6 μM).144 To determine the functional importance of endogenous 
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ROCK and PKC in ET-1-induced vasoconstriction, experiments were performed in the presence 
of ROCK inhibitor H-1152 (3 μM)29,35 or broad-spectrum PKC inhibitor Gö 6983 (10 μM).29 
Vessels were pretreated with antagonists or inhibitors extraluminally for at least 30 minutes. 
Chemicals 
             Drugs for the functional studies were purchased from MilliporeSigma (St. Louis, MO, 
USA) except where specifically stated otherwise. ET-1, sarafotoxin, BQ788, and H-1152 were 
dissolved in water; BQ123, nifedipine, and Bay K8644 were dissolved in ethanol; and PDBu and 
Gö 6983 were dissolved in dimethyl sulfoxide. All subsequent concentrations of these drugs 
were diluted in PSS.28 The final concentration of dimethyl sulfoxide or ethanol in the vessel bath 
less than 0.1% by volume. Vehicle control studies indicated that this final concentration of 
solvent had no effect on vessel viability, vasoconstrictor responses, or maintenance of basal 
tone (data not shown). 
mRNA Isolation and Real Time-Polymerase Chain Reaction Analysis 
             Total RNA was isolated from retinal venules (sample pooled from both eyes) and neural 
retina tissue via RNeasy mini kit (QIAGEN, Crawley, UK), as described in our previous study.145 
The same amount of mRNA for each sample was used to synthesize cDNA with the SuperScript 
III First-Strand Synthesis System (Thermo Fisher Scientific, Waltham, MA, USA). RNA and 
cDNA were quantified using a Nanodrop spectrophotometer (BioTek, Winooski, VT, USA), and 
sequentially processed using real-time polymerase chain reaction (PCR) reagents (PowerUp 
SYBR Green Master Mix, Thermo Fisher Scientific). In order to perform the real-time PCR 
experiments, we used specific primer sets for ETAR (forward primer: 
5’AAGCAGGACAGCCCATTAAG-3’, reverse primer: 5’-CTGCTAGCTGAAGTACTCGGAAC-3’), 
ETBR (forward primer: 5'-GGAGTTGAGATGTGTAAGCTGGTG-3', reverse primer: 5'-
TCTGAGTAGGATGGAGCAAGCAGA-3') and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH; forward primer: 5’-CCACCCACGGCAAGTTCCACGGCA-3’, reverse primer: 5’-
GGTGGTGCAGGAGGCATTGCTGAC-3’). Real-time PCR was performed by monitoring the 
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increase in SYBR Green fluorescence using the Applied Biosystems QuantStudio 6 Flex Real-
Time PCR System (Life Technologies Corporation, Carlsbad, CA, USA). After an initial 
denaturing at 95°C for 2 minutes, reactions were carried out at 95°C for 1 second and 60°C for 
30 seconds for 40 cycles. Relative fold change of each targeted mRNA was determined by the 
2-ΔΔCt method.146 
Western Blot Analysis 
             Western blot analysis was performed as described in our previous study of retinal 
arterioles with slight modification.28,147 Retinal venules (sample pooled from both eyes per pig) 
and neural retina tissue were isolated and sonicated in lysis buffer. The protein content of each 
lysate was determined with the BCA protein assay kit (Pierce, Rockford, IL, USA). Equal 
amounts of protein (2.5 μg for ET-1 receptors and 5 µg for ROCK isoforms and p38) were 
separated by Tris-glycine SDS-PAGE (4%–15% Tris-HCl Ready Gels; Bio-Rad, Hercules, CA, 
USA), transferred onto a nitrocellulose membrane, and incubated with rabbit anti-ETAR or anti-
ETBR polyclonal antibody (1:250 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA; 
Catalog # sc-33535 and sc-33537),28 or mouse anti-ROCK1 or anti-ROCK2 monoclonal 
antibody (1:250 dilution; Santa Cruz Biotechnology, Santa Cruz, CA; Catalog # sc-17794 and 
sc-398519). Membranes were stripped and reprobed with rabbit anti-p38 antibody (1:1000; 
Santa Cruz Biotechnology; Catalog #sc-535), which we previously have shown is highly 
expressed in neural retina tissue.28 After incubation with an appropriate secondary antibody 
(anti-rabbit or anti-mouse IgG, 1:1000; Cell Signaling Technology, Danvers, MA; Catalog # 
7074s and 7076s), the membranes were washed and developed by enhanced 
chemiluminescence (Pierce).  
Data Analysis 
             The maximal diameter of retinal venules was obtained at the end of each functional 
experiment by relaxing vessels with 0.1 mM sodium nitroprusside in EDTA (1 mM)-Ca2+-free 
PSS140 at 5 cmH2O intraluminal pressure. Diameter changes in response to agonists were 
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normalized to the resting diameter and expressed as percentage changes in diameter.28 Data 
are reported as mean ± SEM, and n represents the number of animals (1-2 vessels per pig per 
treatment group for functional studies). Student's t-test or repeated measures two-way analysis 
of variance followed by Bonferroni multiple-range test was used to determine the significance of 
experimental interventions, as appropriate (GraphPad Prism, Version 6.0, GraphPad Software, 
La Jolla, CA, USA). P < 0.05 was considered significant.  
Results 
Retinal Venular Constriction to ET-1 and the Role of ET-1 Receptors 
             Porcine retinal venules (total 50 vessels, 1-2 per pig) were isolated and pressurized at 5 
cmH2O with average maximum diameter of 133 ± 2 µm. These vessels developed stable basal 
tone by constricting to about 92% of maximum diameter within 30 minutes at 36-37°C. In one 
cohort, administration of ET-1 caused constriction of retinal venules in a concentration 
dependent manner (Figure 4A). The threshold concentration of ET-1 for venular constriction 
was about 1 pM and the vessels constricted to about 65% of their resting diameters at 10 nM, 
the highest ET-1 concentration tested. Images of the retinal venular constriction in response to 
0.1 nM ET-1 are shown in Figure 4B. 
             Incubation of the retinal venules with the ETAR antagonist BQ123 did not alter the 
resting vascular diameter but the vasoconstriction elicited by ET-1 was abolished, except for 
about 10% constriction remaining at the highest concentration (10 nM) of ET-1 (Figure 4A). In 
the presence of ETBR antagonist BQ788, neither the resting diameter nor the vasoconstriction 
to ET-1 were altered (Figure 4A). The retinal venules failed to respond to the challenge of ETBR 
agonist sarafotoxin S6c throughout the concentrations tested (Figure 4C). 
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Figure 4. Vasomotor response of isolated and pressurized porcine retinal venules to ET-1. (A) 
Venular diameters were recorded before (R: resting diameter) and after 30-minute treatment (T) 
with an ET-1 receptor antagonist. In the absence of receptor antagonist, retinal venules 
constricted to ET-1 in a concentration dependent manner (Control; n=9). ETAR antagonist 
BQ123 (1 µM; n=5), but not ETBR antagonist BQ788 (0.1 µM; n=5), inhibited venular 
constriction to ET-1. Both antagonists did not alter resting basal tone. *P < 0.05 vs. Control. (B) 
Representative images of a porcine retinal venule at resting diameter and after constriction in 
response to ET-1 (0.1 nM). (C) The response of retinal venules to ETBR agonist sarafotoxin S6c 
was examined (n=6). Reprinted with permission from Yen-Lin Chen, Invest Opthalmol Vis Sci, 
Copyright 2018.
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ET-1 Receptor mRNA and Protein Expressions in Porcine Retinal Venules 
             ETAR and ETBR mRNAs were detected in retinal venules and in neural retina tissue 
devoid of retinal vessels (Figure 5A). The neural retina tissue expressed relatively low amount 
of ET-1 receptor mRNA compared with the venular tissue. At the protein level, immunoblotting 
showed that ETARs and ETBRs were strongly expressed in retinal venules, while only modest 
expression of both ET-1 receptors was detected in neural retina tissue (Figure 5B). 
Roles of Extracellular Ca2+ Entry and L-VOCCs in ET-1-Induced Venular Constriction 
             In the presence of a Ca2+-free solution, retinal venules completely lost basal tone and 
constriction of these vessels to ET-1 was nearly abolished (Figure 6A). At 10 nM ET-1, the 
retinal venules constricted to about 88% of their resting diameter in the absence of extracellular 
Ca2+ versus 65% in the presence of extravascular Ca2+. The L-VOCC inhibitor nifedipine also 
reduced venular basal tone to the same level as in the Ca2+-free solution, but it did not affect the 
constriction of these vessels to ET-1 (Figure 6A). Furthermore, the L-VOCC agonist Bay K8644 
elicited a modest but significant constriction (8% reduction in resting diameter) of retinal venules 
(Figure 6B), which was prevented in the presence of nifedipine (Figure 6B). 
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Figure 5. Molecular analyses of ET-1 receptors in porcine retinal venules. (A) Equal amounts of 
total RNA isolated from porcine retinal venules (RV) and neural retina tissue (RT) were reverse 
transcribed and then analyzed by real-time PCR for detection of ETAR, ETBR, and GAPDH 
mRNAs. The ETAR and ETBR transcripts were normalized to GAPDH expression and presented 
as relative mRNA expression. n = number of pigs studied. (B) Equal amount of protein was 
loaded for Western blot analyses of ETAR and ETBR in retinal venules (RV) and neural retina 
tissue (RT) from pigs. Data represent 4 independent experiments.  Reprinted with permission 
from Yen-Lin Chen, Invest Opthalmol Vis Sci, Copyright 2018. 
55 
Figure 6. Roles of extracellular Ca2+ and L-VOCCs in vasoconstriction of isolated retinal 
venules to ET-1. (A) Venular diameters were recorded before (R: resting diameter) and after 30-
minute treatment (T) of the vessel with Ca2+-free solution (n=10) or L-VOCC inhibitor nifedipine 
(1 µM; n=7). In the absence of treatment (Control; n=12), retinal venules constricted to ET-1 in a 
concentration dependent manner. Both Ca2+-free solution and nifedipine abolished resting tone, 
and the venular constriction to ET-1 was attenuated in the Ca2+-free solution. The 
vasoconstrictor response to ET-1 remained intact in the presence of nifedipine. #P < 0.05 vs. R; 
*P < 0.05 vs. Control. (B) The effect of L-VOCC agonist Bay K8644 (6 µM) on resting diameter
(R) was examined in the absence (n=3) or presence of nifedipine (1 µM; n=3). *P < 0.05 vs. R. 
Reprinted with permission from Yen-Lin Chen, Invest Opthalmol Vis Sci, Copyright 2018. 
56 
Figure 7. Roles of ROCK and PKC in vasoconstriction of isolated retinal venules to ET-1. (A) 
Venular diameters were recorded before (R: resting diameter) and after 30-minute treatment (T) 
with ROCK inhibitor H-1152 (3 µM; n=6) or PKC inhibitor Gö 6983 (10 µM; n=7). In the absence 
of treatment (Control; n=12), retinal venules constricted to ET-1 in a concentration dependent 
manner. The resting diameter of retinal venules was not altered by either drug treatment. The 
ET-1-induced constriction was abolished by H-1152 but not Gö 6983. *P < 0.05 vs. Control. (B) 
Venular diameters were recorded under resting conditions (R) and at different concentrations of 
PKC activator PDBu (n=6). (C) Equal amount of protein was loaded for Western blot analyses of 
ROCK isoforms (ROCK1 and ROCK2) and p38 in retinal venules (RV) and neural retina tissue 
(RT). Data represent 4 independent experiments. Reprinted with permission from Yen-Lin 
Chen, Invest Opthalmol Vis Sci, Copyright 2018. 
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Roles of Rho Kinase and PKC in ET-1-Induced Venular Constriction 
             The Rho kinase inhibitor H-1152 did not significantly alter the resting diameter, but it 
abolished ET-1-induced constriction of retinal venules (Figure 7A). In contrast, PKC inhibitor Gö 
6983 affected neither resting diameter nor vasoconstriction to ET-1 (Figure 7A). Cumulative 
addition of PKC activator PDBu to the vessel bath also did not significantly affect the resting 
diameter of retinal venules (Figure 7B). Immunoblotting showed that both ROCK1 and ROCK2 
isoforms were strongly expressed in retinal venules, while only faint expression of these 
proteins was detected in neural retina tissue (Figure 7C). Sufficient neural retina protein was 
present in these samples because p38 protein expression was strikingly stronger in neural 
retina tissue than in venules (Figure 7C). 
 
Conclusions 
             Although venules are known to play a critical role in regulation of postcapillary pressure 
and capillary fluid exchange,16,17 there is limited study on the direct vasomotor function and 
cognate mechanisms of retinal venules. The salient findings of the present study are that 
pressurized porcine retinal venules exhibit basal tone and constrict to ET-1 through ETAR 
activation. The entry of extracellular Ca2+ and activation of ROCK signaling, independent of L-
VOCC and PKC pathways, appear to mediate the venular constriction to ET-1. We also found 
that extracellular Ca2+ is important in maintenance of basal tone, linking to L-VOCC activity.  
             Studies using isolated vessel preparations have shown that ET-1 directly causes 
constriction of small arterioles28 and veins18 isolated from the porcine retina. Our current study 
corroborates the latter report on porcine retinal veins, as well as extends this earlier finding by 
demonstrating venular constriction to ET-1 and characterizing the underlying mechanism. Our 
findings show that porcine retinal venules develop stable basal tone of about 8% reduction in 
diameter from its maximum value. This level of basal tone is slightly less than the nearly 20% 
tone reported in isolated porcine coronary venules135 and significantly less than the 50-60% tone 
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developed in porcine and human retinal arterioles.35 Our previous study in isolated retinal 
arterioles from pigs showed that the threshold concentration for ET-1-induced constriction is 1 
pM, and the 10 nM concentration elicits a 75% reduction in resting diameter.28 In the present 
study, retinal venules exhibited a similar threshold concentration of 1 pM in response to ET-1, 
but constricted less robustly than the arterioles with only 35% reduction in resting diameter with 
10 nM ET-1 (Figure 4). This venular responsiveness is comparable to that observed in a recent 
ET-1 study in isolated retinal veins from pigs18 and is consistent with the report of the greater 
amount of smooth muscle in retinal arteries than retinal veins.18 It appears that vascular smooth 
muscle, albeit a thin layer, in the porcine retinal venule is sufficient to exert an active response 
to ET-1. These vasoconstrictor responses appear pathophysiologically relevant, because the 
concentrations of ET-1 used in the current study were within the clinical and experimental range 
reported for vitreous fluid (picomolar range)148,149 and the estimated level at the local 
microvasculature (nanomolar range).150 The ability of retinal venules to develop basal tone and 
to constrict in response to ET-1 suggests that these vessels may contribute to the physiological 
and/or pathophysiological regulation of flow resistance, local pressure, and fluid exchange in the 
retinal microcirculation. 
             In the current study, the functional role of specific ET-1 receptor subtypes was 
characterized by examining the vascular response to ET-1 in the presence of ETAR or ETBR 
antagonist. The concentration-dependent constriction of retinal venules was nearly abolished by 
pharmacologic ETAR blockade (Figure 4). These results are consistent with the major 
contribution of ETARs in retinal arteriolar constriction to ET-1 reported in our previous studies.28 
By contrast, ETBR blockade (BQ778) did not affect ET-1-induced venular constriction, 
suggesting that ETBR does not contribute to this vasomotor response. This contention is 
supported by the efficacy of BQ778 and the observed unresponsiveness of the vessel to the 
ETBR agonist sarafotoxin. Sarafotoxin did not alter resting vascular tone or cause 
vasoconstriction in the present study (Figure 4). Moreover, the same concentrations of 
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sarafotoxin were reported in our previous study to elicit significant constriction of porcine retinal 
arterioles in a manner sensitive to ETBR blockade (BQ778).28 It appears that ETBR plays little 
role in retinal venular constriction to ET-1, a mechanism that differs from their upstream 
arterioles, in which both ETARs and ETBRs contribute to the vasoconstriction to ET-1,28,34 at 
least under normal physiological conditions. At the molecular level, we showed expression of 
both ETAR and ETBR mRNA and protein in isolated porcine retinal venules (Figure 5). The 
mRNA and protein expressions of both ET-1 receptor subtypes were also detected in the neural 
retina tissue but were strikingly lower than those in the retinal venules. Expression of both ET-1 
receptor subtypes in the neural retina layers is also supported by the immunohistochemical data 
in pigs151 and rodents,152-154 but the quantitative comparison with retinal vascular tissue is not 
available. Although we can detect the mRNA and protein levels in retinal venules, the distinct 
cellular distribution, i.e., endothelial vs. smooth muscle cells, of ETARs and ETBRs in the retinal 
venules requires further investigation. Collectively, our functional and molecular findings support 
the dominant role of ETARs in mediating ET-1-induced constriction of porcine retinal venules. 
             Vascular smooth muscle contraction is regulated by changes in intracellular Ca2+ with 
Ca2+ entry occurring through several types of channels, including L-VOCCs.155,156 Although 
activation of ETARs elicits Ca2+ signaling in blood vessels, the specific channels involved are 
diverse depending on the vascular bed and species.23 The potential roles of extracellular Ca2+ 
and L-VOCCs in basal tone and ET-1-induced constriction of retinal venules have not been 
explored previously. In the present study, the resting basal tone was abolished in the absence 
of extracellular Ca2+ or during exposure to nifedipine, suggesting that extracellular Ca2+ and L-
VOCCs are indispensable for maintenance of basal tone at physiologic intraluminal pressure. 
The constriction of retinal venules to ET-1 also required Ca2+ entry, because ET-1 failed to elicit 
vasoconstriction in the absence of extracellular Ca2+ (Figure 6). However, the inability of 
nifedipine to prevent the ET-1-induced vasoconstriction indicates that L-VOCCs do not mediate 
the extracellular Ca2+ entry. The efficacy of nifedipine in blocking L-VOCCs was supported by 
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the obliteration of the venular constriction to L-VOCC activator Bay K 8644 (Figure 6). Our 
finding with ET-1 is consistent with the lack of an effect of L-VOCC blockade on the ET-1-
induced contraction of rat mesenteric veins157 and our previous results with porcine retinal 
arterioles.29 It seems that the pathway of Ca2+ entry for vasoconstriction in response to ET-1 in 
retinal venules is distinct from that used for basal tone maintenance in that the former does not 
involve L-VOCCs. The specific smooth muscle channels responsible for ET-1-induced 
constriction in retinal venules remains unclear, and it will be the subject of future investigation. 
             It is generally accepted that the process of smooth muscle contraction is coupled to the 
level of myosin light chain (MLC) phosphorylation,158 which is modulated by Ca2+-dependent 
activity of MLC kinase68,159,160 and by MLC phosphatase.161 Protein kinases such as ROCK and 
PKC can inhibit MLC phosphatase leading to enhanced MLC phosphorylation162-164 and 
subsequent contraction of vascular smooth muscle.68,161 Both ROCK and PKC have been 
shown to be possible signaling molecules modulating contractile myofilament sensitivity to Ca2+, 
thus regulating the force of smooth muscle contraction.165,166 However, it is unknown whether 
ET-1 also uses these signaling molecules in the retinal venules to exert its contractile action. 
We found that specific pharmacological blockade of ROCK prevented constriction of porcine 
retinal venules to ET-1 without altering basal tone (Figure 7). In the presence of PKC inhibitor 
Gö 6983, both resting tone and ET-1-induced vasoconstriction remained intact. Moreover, the 
retinal venules were not responsive to the PKC activator PDBu (Figure 7). This observation 
contrasts with potent PDBu-induced constriction of porcine retinal arterioles, which was blocked 
by PKC inhibitor Gö 6983 in our previous studies.29,34 Overall, these results suggest that 
activation of ROCK, but not PKC, signaling is involved in the venular constriction to ET-1. 
Furthermore, we detected both ROCK isoforms (ROCK1 and ROCK2) at the protein level in 
retinal venules. Although the ROCK2 isoform has been suggested to play a major role in 
smooth muscle contraction,167 the cellular distributions and their individual functional linking to 
extracellular Ca2+ entry in retinal venules remain unknown and warrant further investigation.  
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             A fundamental understanding of vasomotor regulation mechanisms of retinal venules in 
response to ET-1 is important, because increased local or plasma levels of this peptide in the 
retina have been implicated in the pathogenesis of RVO and diabetic retinopathy.13,139,168 A 
complication of RVO169 and late stage diabetic retinopathy170 is the onset of edema and fluid 
accumulation in the retina contributing to neural retina dysfunction and blindness. Constriction of 
retinal veins by ET-1 may increase retinal venous pressure, which could promote edema and 
reduction in retinal perfusion pressure under disease states.13 This notion is supported by 
clinical studies reporting elevation of retinal venous pressure and reduced retinal blood flow in 
patients with RVO171,172 and diabetic retinopathy,10,14,86 including those with diabetic macular 
edema.85 Taken together, these clinical observations along with our current findings underpin 
the concept that retinal vein constriction to elevated levels of ET-1 contributes to the 
pathogenesis of retinal diseases such as RVO and diabetes.11,13,14,168 Evaluation of the impact of 
experimental diabetes105 on ET-1-induced constriction of retinal venules could help corroborate 
this hypothesis. 
             In summary, we found that isolated porcine retinal venules develop modest basal tone 
and constrict markedly to ET-1 in an extracellular Ca2+-dependent manner. Although L-VOCCs 
play a critical role in maintaining basal tone of retinal venules, they do not contribute to the ET-1 
induced vasoconstriction. Retinal venules express both ETARs and ETBRs, but ETARs play a 
dominant role in vasoconstriction to ET-1. It appears that activation of ROCK but not PKC 
signaling mediates the venular constriction to ET-1. This study provides important insight into 
the mechanisms of ET-1-induced constriction of retinal venules and lays a foundation for future 
research to better understand vasomotor regulation of these microvessels under physiological 
and pathophysiological conditions in the retina 
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III. ACUTE AND CHRONIC HYPERGLYCEMIA ENHANCE 
CONSTRICTION OF RETINAL VENULES VIA ACTIVATION OF 




             Retinopathy is one of the most common microvascular complications of diabetes 
mellitus and a major cause of vision impairment and blindness in working-age adults.1 
Hyperglycemia, a hallmark of diabetes, is closely linked to the retinal pathology including 
progression from early disruption of retinal perfusion for proper oxygen supply to the 
development of edema and fluid accumulation during the late stages of the disease.2 Although 
alteration of microcirculatory function in the retina is considered a critical event contributing to 
tissue edema with diabetes, the precise vasomotor regulatory mechanisms remain unclear. It is 
well recognized that venular resistance influences hydrostatic pressure and fluid homeostasis at 
the level of the capillaries.3,4 Constriction of retinal venules is expected to increase retinal 
venous resistance and pressure, which could consequently reduce retinal perfusion and 
promote edema under disease states such as diabetes.5,6 In accord with this idea, clinical 
evidence has shown increased retinal venous pressure and decreased retinal blood flow in 
patients with diabetic retinopathy,7,8 including those with diabetic macular edema.9 However, it is 
unclear whether diabetes or hyperglycemia affects responses of retinal venules to endogenous 
vasoconstrictors. The potent vasoconstrictor endothelin-1 (ET-1) has been implicated in the 
pathogenesis of diabetic retinopathy based in part on elevated levels of this peptide in the 
retinal tissue10,11 of diabetic rats and vitreous fluid12 of human patients with diabetic retinopathy. 
Elevated plasma/serum or retinal tissue levels of other vasoconstrictors, such as thromboxane 
A2 (TXA2),13 norepinephrine14 and angiotensin II,15 have also been detected in experimental 
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diabetes. Therefore, it is important to investigate whether diabetes/hyperglycemia alters venular 
reactivity to these endogenous vasoconstrictors in the retina.    
             It is generally accepted that Ca2+ entry into the vascular smooth muscle cells triggers 
vasoconstriction.16 In some blood vessels, this process is mediated by activation of L-type 
voltage-operated Ca2+ channels (L-VOCCs),16 calcium release-activated calcium (CRAC) 
channels,17 or transient receptor potential-canonical (TRPC) channels.17-20 However, our recent 
study shows that L-VOCCs play no role in retinal venular constriction to ET-1 despite the fact 
that extracellular Ca2+ entry is required.21 An additional mechanism for Ca2+ entry is activation of 
the sodium-calcium exchanger (NCX).22 The antiporter membrane protein, NCX, can operate in 
both forward and reverse modes. The forward-mode NCX prevents Ca2+ overload in cells and 
uses the energy that is stored in the electrochemical gradient of sodium by allowing three 
sodium ions to flow down their gradient across membranes in exchange for export of one Ca2+ 
ion.23 However, when intracellular levels of sodium ions rise beyond a critical point, especially 
under pathological conditions, NCX begins importing Ca2+ ions in the reverse mode.23 
Interestingly, previous studies demonstrated that ET-1 can exert both inotropic and hypertrophic 
effects on cardiomyocytes by promoting extracellular Ca2+ influx through the sodium-hydrogen 
exchanger (NHE)-dependent or protein kinase C (PKC)-dependent reverse-mode NCX.22,24,25 
The activation of reverse-mode NCX also has been shown to cause increased Ca2+ entry in 
cultured cardiomyocytes exposed to high levels of glucose.26  
             Mitogen-activated protein kinases (MAPKs) are a highly conserved family of 
serine/threonine protein kinases, which are believed to play important roles in vasoactive 
responses.27-29 There are three isoforms: c-Jun N-terminal kinase (JNK), p38 MAPK, and 
extracellular signal–regulated kinases (ERK). Previous evidence shows that JNK signaling 
contributes in part to norepinephrine- and ET-1-induced contraction of rat aorta.27,28 In addition, 
thromboxane A2 (TXA2) receptor agonist U46619 increased JNK signaling in rat aortic smooth 
muscle cells.30 High glucose can increase activity of NHE in canine distal nephron cells through 
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enhanced p38 MAPK and ERK signaling.31 The activation of p38 MAPK-has also been shown to 
contribute retinal endothelial and neural retina dysfunction in diabetic rats.32,33 However, 
whether NHE and reverse-mode NCX linked to MAPK and/or PKC signaling contribute to 
agonist-induced constriction of retinal venules under normal and diabetic/hyperglycemic 
conditions have not been investigated. Therefore, we addressed these issues by examining the 
direct response of isolated retinal venules to ET-1 and other vasoconstrictors (U46619, 
norepinephrine, phenylephrine, and angiotensin II) and investigating whether acute and chronic 
hyperglycemia influence these vasoconstrictions via NHE-dependent or PKC-dependent 
reverse-mode NCX activation. In addition, the contribution of MAPK pathways to vasoactive 
responses of retinal venules to ET-1 under euglycemia and chronic hyperglycemia were 
evaluated. We also assessed the impact of hyperglycemia on vitreous humor levels of 
vasoconstrictor substances and mRNA expression of the target receptors for vasoconstriction in 
retinal venules using biochemical and molecular tools.  
 
Methods 
Porcine Diabetes Model 
             All animal procedures were performed in accordance with the ARVO Statement for the 
Use of Animals in Ophthalmic and Vision Research and were approved by the Baylor Scott & 
White Health Institutional Animal Care and Use Committee. Domestic (Yorkshire) male pigs 
(age range, 6-10 wk; weight range, 9-20 kg) were purchased from Real Farms (San Antonio, 
TX). Diabetes (i.e., chronic hyperglycemia) was induced by selective ablation of pancreatic β-
cells with intravenous injection of streptozocin (STZ, Zanosar®, 200 mg/kg in saline) via an ear 
vein (48 pigs), as described in detail in our previous study.34,35 The control euglycemic group 
was intravenously injected with saline (59 pigs). Fasting blood glucose levels were obtained 
every other day using a Bayer Contour glucometer (Bayer Corporation, Pittsburgh, PA). Pigs 
were treated with insulin (Humulin® 70/30, 2-8 units; Lilly, Indianapolis, IN) if blood glucose was 
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sustained above 600 mg/dl to keep the level between 250 and 600 mg/dl. After 2 weeks, pigs 
were sedated with Telazol (4-8 mg/kg, intramuscularly), anesthetized with 2-5% isoflurane, and 
intubated. The eyes were harvested as described previously.36 
Isolation and Cannulation of Retinal Venules 
             Single second-order retinal venules (1 to 1.5 mm in length without side branches) were 
dissected from surrounding neural/connective tissues and then cannulated on each end with 
glass micropipettes containing physiological saline solution (PSS) with 5 mM D-glucose and 1% 
albumin.21 In another cohort, 25 mM D-glucose in the PSS was used. Vessels were pressurized 
to 5 cmH2O intraluminal pressure without flow by two independent pressure reservoirs and their 
inner diameter was recorded using videomicroscopic techniques throughout the experiments, as 
described previously.21  
Study of Vasomotor Function 
             Cannulated, pressurized retinal venules were bathed in PSS-albumin at 36-37°C to 
allow development of basal tone (stable within 60-90 minutes). To evaluate the effect of chronic 
hyperglycemia on vasomotor function, diameter changes to cumulative administration of ET-1 (1 
pM to 10 nM; Bachem, Torrance, CA), TXA2 receptor agonist U46619 (0.1 nM to 1 µM; Cayman 
Chemical, Ann Arbor, MI), angiotensin II (0.1 nM to 10 µM; MilliporeSigma, St. Louis, MO), non-
selective α-adrenergic receptor (AR) agonist norepinephrine (1 nM to 10 µM; Cayman 
Chemical), or α1-AR agonist phenylephrine (1 nM to 10 µM; Cayman Chemical) were recorded 
and compared in vessels isolated from diabetic and control pigs. Retinal venules were exposed 
to each concentration of agonist for 10 minutes until a stable diameter was attained. The 
contribution of ETA receptors (ETARs) in vasoconstriction to ET-1 was evaluated after incubation 
with respective antagonist BQ123 (1 μM).21 The contribution of TXA2 receptors (TXA2Rs) in 
vasoconstriction to U46619 was examined in the presence of respective antagonist SQ29548 
(10 μM).37 The relative roles of α1-ARs and α2-ARs in vasoconstriction to norepinephrine or 
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phenylephrine were evaluated in the presence of selective α1-AR antagonist prazosin 
hydrochloride (10 μM)38 or α2-AR antagonist atipamezole (10 μM).39 The contributions of TRPC3 
and CRAC channels in vasoconstriction to ET-1 were evaluated after incubation with TRPC3 
inhibitor Pyr3 (10 μM)40 and CRAC channel inhibitor BTP2 (1 μM; EMD Millipore, Billerica, MA, 
USA),41 respectively. The role of reverse-mode NCX in agonist-induced constrictions was 
examined in the presence of its selective inhibitors KB-R7943 (10 μM)42 or SEA0400 (10 µM).43 
The contributions of PKC and NHE in vasoconstriction to ET-1 were evaluated after incubation 
with PKC antagonist Gö 6983 (10 μM; EMD Millipore, Billerica, MA, USA)44 and NHE inhibitor 
cariporide (1 μM).45 Vasomotor response to PKC activator phorbol-12,13-dibutyrate (PDBu; 0.1 
µM to 10 µM) was also evaluated. In some vessels, the role of L-VOCCs in the vasoconstriction 
to ET-1 was evaluated in the presence of L-type Ca2+ channel antagonist nifedipine (1 μM).21 To 
assess the involvement of MAPKs in the chronic hyperglycemia-induced effect, the vasomotor 
responses of retinal venules to ET-1 were examined following treatment with p38 kinase 
inhibitor SB203580 (0.1 μM; EMD Millipore, Billerica, MA, USA),46 ERK inhibitor PD98059 (10 
μM; EMD Millipore, Billerica, MA, USA),47 or JNK inhibitor SP600125 (10 μM; EMD Millipore, 
Billerica, MA, USA).27 All vessels were pretreated with antagonists or inhibitors extraluminally for 
at least 30 minutes. In order to assess the activity of reverse-mode NCX in retinal vessels, 
resting diameter of venules was measured during exposure to low-Na+ (1.4 mM) PSS for 20 
minutes and then in the presence of normal-Na+ (146.2 mM) PSS for 20 minutes. To control for 
changes in osmolarity, N-methyl D-glucamine was substituted for NaCl in low-Na+ PSS.  
             The acute effect of high glucose on vasoconstrictions to ET-1, U46619, and 
norepinephrine was evaluated after intraluminal incubation of vessels from nondiabetic pigs (49 
pigs) with 25 mM D-glucose for 2 hours,34 and the results were compared with the treatment 
with normal 5 mM D-glucose as control. The contribution of NCX in agonist-induced 
vasoconstrictions was evaluated after co-incubation of 5 mM or 25 mM glucose-PSS with KB-
R7943 (10 μM) for 2 hours. In some vessels, vasoconstriction to ET-1 (0.1 nM) was assessed in 
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the presence of 20 mM L-glucose (MilliporeSigma) plus 5 mM D-glucose to determine the 
stereospecific impact of glucose on these responses. Osmolarity in all the 25 mM glucose 
solutions was balanced to 290 mOsm by reducing the NaCl concentration to avoid a potential 
hyperosmolarity effect.  
Chemicals 
             Drugs were obtained from Tocris Cookson (Ellisville, MO) except as specifically stated 
otherwise. ET-1, angiotensin II and PDBu were dissolved in water; BQ123 and nifedipine were 
dissolved in ethanol; and phenylephrine, norepinephrine, U46619, SQ29548, prazosin 
hydrochloride, atipamezole, Pyr3, BTP2, Gö 6983 KB-R7943, SEA0400, cariporide, SB203580, 
PD98059, and SP600125 were dissolved in dimethyl sulfoxide. Subsequent concentrations of 
these drugs were diluted in PSS. The final concentration of dimethyl sulfoxide or ethanol in the 
vessel bath did not exceed 0.1% by volume. Vehicle control studies indicated that this final 
concentration for these two solvents had no effect on vessel viability, vasoconstrictor responses, 
or maintenance of basal tone (data not shown). 
mRNA Isolation and Real-Time Polymerase Chain Reaction (PCR) Analysis 
             Total RNA was isolated from retinal venules (sample pooled from both eyes) and neural 
retina tissue via RNeasy mini kit (QIAGEN, Crawley, UK), as described previously.21,48 To 
perform real-time PCR experiments, specific primer sets presented in the Table were used. The 
same amount of total RNA for each sample was used to synthesize cDNA followed by real-time 
PCR with the Applied Biosystems QuantStudio 6 Flex Real-Time PCR System (Life 
Technologies Corporation, Carlsbad, CA), as described previously.21  
Measurements of ET-1 and TXB2 in the Vitreous Humor 
             Vitreous humor was obtained after harvesting the eyes from control and diabetic pigs. 
Undiluted vitreous samples were centrifuged at 12,000 rpm for 10 minutes at 4°C, and the 
supernatants were then stored at -80°C for subsequent analysis within 3 months. Levels of ET-1 
protein and TXB2, a stable TXA2 lipid metabolite, in the vitreous were measured using an ET-1 
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ELISA kit (ADI-900-020A; Enzo Life Sciences Inc., Farmingdale, NY) and a TXB2 ELISA kit 
(ADI-900-002; Enzo Life Sciences Inc.), respectively, according to the manufacturer's 
instructions. 
Data Analysis 
             At the end of each functional experiment, the vessel was relaxed with 0.1 mM sodium 
nitroprusside in EDTA (1 mM)-Ca2+-free PSS to obtain its maximum diameter at 5 cmH2O 
intraluminal pressure.21 Diameter changes in response to agonists were normalized to the 
resting diameter and expressed as percentage changes in diameter.21 Data are reported as 
mean ± SEM, and n represents number of vessels (1 per pig for each agonist and treatment 
groups for functional studies) or pigs (for molecular/biochemical studies). Student's t-test or 
repeated measures two-way analysis of variance followed by Bonferroni multiple-range test was 
used to determine the significance of experimental interventions, as appropriate (GraphPad 















Table 2. Primer sets used for real-time PCR 
 
ETA Receptor, endothelin A receptor; TXA2 Receptor, thromboxane A2 receptor; NCX1, 2, 3, 































































Agonist-induced Constriction of Retinal Venules from Euglycemic Pigs 
             Porcine retinal venules (total 100 vessels in Fig. 8) were isolated and pressurized at 5 
cmH2O with an average maximum diameter of 130 ± 1 µm. All vessels in this study developed 
similar levels of stable basal tone by constricting to about 93% of maximum diameter. 
Administration of ET-1, U46619, or norepinephrine caused concentration-dependent constriction 
of retinal venules from nondiabetic pigs (Fig. 8). Threshold concentrations of ET-1 and U46619 
for venular constrictions were about 1 pM and 0.1 nM, respectively. Maximum vasoconstrictions 
were about 50% of resting diameters at the highest concentrations of 10 nM ET-1 and 1 µM 
U46619 (Fig. 8). The threshold concentration of norepinephrine for venular constriction was 
about 0.1 µM, and the maximum constriction was about 75% of resting diameter at the highest 
concentration of 10 µM (Fig. 8). However, administration of angiotensin II or phenylephrine 






















Figure 8. Vasomotor response of isolated and pressurized porcine retinal venules to 
vasoconstrictors. Venular diameters were recorded before (R: resting diameter) and after 
administration of vasoconstrictor agonists. ET-1 (n = 36), U46619 (n = 33), and norepinephrine 
(n = 13) significantly constricted retinal venules in a concentration-dependent manner. 
Angiotensin II (n = 5) and phenylephrine (n = 13) caused only slight constriction in retinal 












Effect of Chronic Hyperglycemia on Retinal Venular Constriction 
             Retinal venules isolated from the 2-week diabetic pigs (chronic hyperglycemia: 449 ± 19 
mg/dl) and age-matched control pigs (euglycemia: 97 ± 3 mg/dl) developed a comparable level 
of basal tone by constricting to about 93% of maximum diameter. However, retinal venules from 
diabetic pigs exhibited enhanced constrictions to ET-1, U46619, and norepinephrine (Fig. 9A). 
Maximum constrictions to the highest concentrations of these three agonists was about 25-30% 
greater in diabetic than control venules. In contrast, angiotensin II and phenylephrine did not 
alter basal tone of retinal venules except for modest constriction (about 10%) observed at 10 
µM, and there was no enhanced vasoconstriction with diabetes (data not shown). 
Effect of Acute Hyperglycemia on Retinal Venular Constriction 
             Retinal venules isolated from nondiabetic pigs developed a comparable level of basal 
tone after intraluminal exposure to normal (5 mM) or high (25 mM) level of D-glucose for 2 
hours. Vasoconstrictions to ET-1, U46619, and norepinephrine (Fig. 9B) were significantly 
increased by high D-glucose with increased maximum constriction about 15-25% compared to 
the vessels exposed to normal D-glucose. The high L-glucose solution (20 mM L-glucose plus 5 










Figure 9. Effect of chronic and acute hyperglycemia on vasomotor reactivity of isolated retinal 
venules to vasoconstrictors. Venular diameters were recorded before (R: resting diameter) and 
after administration of vasoconstrictor agonists. (A) Chronic hyperglycemia for 2 weeks in 
diabetic pigs significantly enhanced ET-1- (Control, n = 36; Diabetes, n = 34), U46619- (Control, 
n = 15; Diabetes, n = 14), and norepinephrine-induced (Control, n = 6; Diabetes, n = 7) 
constrictions of retinal venules. *P < 0.05 vs. Control. (B) For retinal venules isolated from 
euglycemic pigs, concentration-dependent constrictions to ET-1 (Control, n = 14; High Glucose, 
n = 12), U46619 (Control, n = 15; High Glucose, n = 15), and norepinephrine (Control, n = 11; 
High Glucose, n = 10) were significantly greater after 2-hour intraluminal exposure to high 




Figure 10. Effects of hyperglycemia on ETAR-mediated constriction to ET-1, ETAR expression, 
and vitreous levels of ET-1. (A) Venular diameters were recorded before (R: resting diameter) 
 83 
and after 30-minute treatment (T) with ETAR antagonist BQ123 prior to administration of ET-1. 
In the absence of BQ123, chronic hyperglycemia for 2 weeks in diabetic pigs significantly 
enhanced ET-1-induced constriction of retinal venules (Control, n = 7; Diabetes, n = 8). BQ123 
(1 µM) nearly abolished both of these responses. *P < 0.05 vs. Control. (B) Constriction of 
retinal venules from euglycemic pigs to ET-1 (0.1 nM) was significantly greater after 2-hour 
intraluminal exposure to high glucose (25 mM; n = 8) than to control normal glucose (5 mM; n = 
7). BQ123 (1 µM) abolished ET-1-induced constriction of retinal venules under control and high 
glucose exposures. *P < 0.05 vs. Control; #P < 0.05 vs. ET-1 only. Equal amounts of total RNA 
isolated from porcine retinal venules and neural retina tissue after 2 weeks of euglycemia 
(Control) and chronic hyperglycemia (Diabetes) were reverse transcribed and then analyzed by 
real-time PCR for detection of ETAR and GAPDH mRNAs. (C) After normalization with GAPDH, 
the ETAR was not differentially expressed (presented as relative mRNA expression) between 
Control (n = 10) and Diabetes (n = 12) in retinal venules. The ETAR expression in neural tissue 
was not different between Control (n = 14) and Diabetes (n = 13) but was less than in venules. n 
= number of pigs studied. *P < 0.05 vs. Venules. (D) Chronic hyperglycemia for 2 weeks in 
diabetic pigs significantly increased expression level of ET-1 in the vitreous humor (Control, n = 











Venular Receptors and Vitreous Humor Level of ET-1 and TXB2 
             The ET-1-induced constriction of retinal venules exposed to euglycemia or 
hyperglycemia (chronic and acute) was abolished in the presence of ETAR antagonist BQ123 
(Figs. 10A and 10B). There was a greater amount of ETAR mRNA expressed in retinal venules 
than in neural retina under control and diabetic conditions, but the expression in both tissues 
was not influenced by chronic hyperglycemia (Fig. 10C). The ET-1 protein level was greater in 
the vitreous isolated from diabetic (2.9 ± 0.4 pg/ml ≈ 1.2 ± 0.2 pM) compared to control (1.4 ± 
0.2 pg/ml ≈ 0.6 ± 0.1 pM) pigs (Fig. 10D).  
             Constriction of retinal venules from control pigs to U46619 was completely blocked in 
the presence of TXA2R antagonist SQ29548 (Fig. 11A). The TXA2R mRNA expression in retinal 
venules was greater than that in neural retina, but in both tissues it was not altered by diabetes 
(Fig. 11B). Concentrations of TXB2, the stable TXA2 metabolite, were comparable in the vitreous 
isolated from control (24 ± 4 pg/ml ≈ 65 ± 9 pM) and diabetic (17 ± 3 pg/ml ≈ 47 ± 9 pM) pigs 
(Fig. 11C). 
             The α2-AR antagonist atipamezole abolished norepinephrine-induced constriction of 
retinal venules from control pigs, whereas α1-AR antagonist prazosin did not alter this 
vasoconstriction (Fig. 12A). Expression of α1-AR mRNA in retinal venules and neural retina 
tissue was unaffected by diabetes, but it was less in neural retina than in venules only after 
diabetes (Fig. 12B). The α2A-AR mRNA in venules was greater than that in neural retina and in 









Figure 11. Role of TXA2R activation in U46619-induced constriction of retinal venules and 
effects of chronic hyperglycemia on TXA2R expression and vitreous levels of TXB2. (A) Venular 
diameters were recorded before (R: resting diameter) and after 30-minute treatment (T) with 
TXA2R antagonist SQ29548 prior to administration of U46619. In the absence of SQ29548, 
retinal venules from euglycemic pigs constricted to U46619 in a concentration dependent 
manner (Control; n = 7). SQ29548 (10 µM) abolished venular constriction to U46619 (n = 7). *P 
< 0.05 vs. Control. (B) Equal amounts of total RNA isolated from porcine retinal venules and 
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neural retina tissue after 2 weeks of euglycemia (Control) and chronic hyperglycemia (Diabetes) 
were reverse transcribed and then analyzed by real-time PCR for detection of TXA2R and 
GAPDH mRNAs. The TXA2R transcript was normalized to GAPDH expression and presented as 
relative mRNA expression. The TXA2R expression was not different between Control (n = 9) 
and Diabetes (n = 7) in retinal venules or in neural retina tissue (Control, n = 10; Diabetes, n = 
10), but it was less in neural retina than in venules. n = number of pigs studied. *P < 0.05 vs. 
Venules. (C) A similar expression level of TXB2 (stable TXA2 metabolite) was detected in the 
vitreous humor after 2 weeks of euglycemia (Control, n = 15) and chronic hyperglycemia 
















Figure 12. Role of α-AR activation in norepinephrine-induced constriction of retinal venules and 
effects of chronic hyperglycemia on α-AR expression. (A) Venular diameters were recorded 
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before (R: resting diameter) and after 30-minute treatment (T) with an α-AR antagonist prior to 
administration of norepinephrine. In the absence of receptor antagonist, retinal venules from 
euglycemic pigs constricted to norepinephrine in a concentration dependent manner (Control; n 
= 11). α2-AR antagonist atipamezole (10 µM; n = 5), but not α1-AR antagonist prazosin (10 µM; 
n = 6), inhibited venular constriction to norepinephrine. *P < 0.05 vs. Control. Equal amounts of 
total RNA isolated from porcine retinal venules and neural retina tissue after 2 weeks of 
euglycemia (Control) and chronic hyperglycemia (Diabetes) were reverse transcribed and then 
analyzed by real-time PCR for detection of α-ARs and GAPDH mRNAs. The α-AR transcript 
was normalized to GAPDH expression and presented as relative mRNA expression. (B) The α1-
AR mRNA expression was not different between Control (n = 9) and Diabetes (n = 8) in retinal 
venules or in neural retina tissue (Control, n = 10; Diabetes, n = 10), but it was less in neural 
retina than in venules after diabetes. *P < 0.05 vs. Venules. (C) The α2A-AR mRNA was not 
differentially expressed between Control (n = 9) and Diabetes (n = 8) in retinal venules or in 
neural retina tissue (Control, n = 10; Diabetes, n = 9), but it was less in neural retina than in 
venules under both conditions. n = number of pigs studied. *P < 0.05 vs. Venules. 
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Role of Reverse-mode NCX in Hyperglycemia-enhanced Venular Constriction 
             The low Na+ PSS induced reverse-mode NCX inhibitor KB-R7943-dependent 
constriction of retinal venules (A. 2). In the presence of reverse-mode NCX inhibitor KB-R7943, 
retinal venules exposed to euglycemia or hyperglycemia (chronic and acute) lost about 50% of 
basal tone (Fig. 13). The KB-R7943 treatment also prevented the enhanced constrictions of 
retinal venules to ET-1 (Figs. 13A and 13B), U46619 (Figs. 13A and 13B) and norepinephrine 
(Figs. 13A and 13B) under hyperglycemia (chronic and acute) without altering normal 
vasoconstrictor responses in euglycemia. An additional reverse-mode NCX inhibitor SEA0400 
also reduced basal tone nearly 44% and blocked the enhanced venular constriction to 0.1 nM 
ET-1 under chronic hyperglycemia, but it did not affect ET-1-induced vasoconstriction under 
euglycemia (A. 3). The L-VOCC inhibitor nifedipine reduced basal tone of venules exposed to 
euglycemia or hyperglycemia (acute and chronic) to the same level induced by KB-R7943, but it 
did not affect the enhanced vasoconstrictions to ET-1 by acute or chronic hyperglycemia (A. 4). 
The ET-1-induced constriction of retinal venules under euglycemia was also not altered in the 
presence of TRPC3 inhibitor Pyr3 or CRAC channel inhibitor BTP2 (A. 5). The amount of NCX1-
3 isoform mRNA expressions in retinal venules (A. 6A) was greater than that in neural retina 
tissue (A. 6B) but was unaltered by chronic hyperglycemia.   
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Figure 13. Role of reverse-mode NCX in enhanced agonist-induced constriction of isolated 
retinal venules during chronic and acute hyperglycemia. Venular diameters were recorded 
before (R: resting diameter) and after 60-minute treatment (T) with reverse-mode inhibitor KB-
R7943 prior to administration of vasoconstrictor agonists. (A) In the absence of KB-R7943, 
chronic hyperglycemia for 2 weeks in diabetic pigs significantly increased ET-1-, U46619- and 
norepinephrine-induced constrictions of retinal venules (Control, n = 6-10 for each agonist; 
Diabetes, n = 6-12 for each agonist). KB-R7943 (10 µM) prevented the enhanced constriction of 
retinal venules to ET-1 (Diabetes / KB-R7943, n = 8), U46619 (Diabetes / KB-R7943, n = 5), 
and norepinephrine (Diabetes / KB-R7943, n = 5) after chronic hyperglycemia (Diabetes), but it 
did not alter these agonist-induced vasoconstrictor responses during euglycemia (Control / KB-
R7943, n = 5-7 for each agonist). *P < 0.05 vs. Control. (B) In the absence of KB-R7943, 2-hour 
intraluminal exposure of retinal venules isolated from euglycemic pigs to high glucose (25 mM) 
significantly increased ET-1-, U46619- and norepinephrine-induced constrictions (Control, n = 6-
11 for each agonist; High Glucose, n = 7-10 for each agonist). KB-R7943 (10 µM) prevented the 
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enhanced constrictions to ET-1 (High Glucose / KB-R7943, n = 6), U46619 (High Glucose / KB-
R7943, n = 7) and norepinephrine (High Glucose / KB-R7943, n = 9) after acute hyperglycemia, 
but it did not alter these agonist-induced vasoconstrictor responses in the presence of control 
normal (5 mM) glucose (Control / KB-R7943, n= 6-10 for each agonist). *P < 0.05 vs. Control. 
 
 
Role of PKC and NHE in Hyperglycemia-enhanced Venular Constriction 
             The PKC inhibitor Gö 6983 did not affect basal tone of venules or their 
vasoconstrictions to ET-1 after euglycemia or chronic hyperglycemia (Fig. 14A). In addition, 
exposure of vessels to the PKC activator PDBu did not significantly alter resting diameter under 
euglycemia or chronic hyperglycemia (Fig. 14B). In the presence of NHE inhibitor cariporide, 
retinal venules exposed to euglycemia or hyperglycemia (chronic and acute) lost about 50% of 
basal tone. The cariporide treatment prevented the enhanced constrictions of retinal venules to 
ET-1 (Fig. 15A) and U46619 (Fig. 15B) under chronic hyperglycemia without altering normal 














Figure 14. Role of PKC in ET-1-induced constriction of retinal venules after chronic 
hyperglycemia. (A) Venular diameters were recorded before (R: resting diameter) and after 30-
minute treatment (T) with PKC inhibitor Gö 6983 (10 µM) prior to administration of ET-1. The 
retinal venules from euglycemic pigs constricted concentration-dependently to ET-1 (Control, n 
= 8), and the vasoconstriction to ET-1 was enhanced by chronic hyperglycemia (Diabetes, n = 
8). Gö 6983 did not alter the constriction to ET-1 in vessels from euglycemic pigs (Control / Gö 
6983, n = 7) or the enhanced ET-1-induced vasoconstriction in chronic hyperglycemic pigs 
(Diabetes / Gö 6983, n = 5). *P < 0.05 vs. Control. (B) The response of retinal venules to PKC 
agonist PDBu was examined during euglycemia (Control, n = 7) and chronic hyperglycemia 










Figure 15. Role of NHE in enhanced ET-1-induced and U46619-induced constriction of isolated 
retinal venules during chronic hyperglycemia. Venular diameters were recorded before (R: 
resting diameter) and after 60-minute treatment (T) with NHE inhibitor cariporide prior to 
administration of vasoconstrictor agonists. (A) In the absence of cariporide, chronic 
hyperglycemia for 2 weeks in diabetic pigs significantly increased ET-1-induced constrictions of 
retinal venules (Control, n = 14; Diabetes, n = 17). Cariporide (1 µM) prevented the enhanced 
constriction of retinal venules to ET-1 (Diabetes / Cariporide, n = 8) after chronic hyperglycemia 
(Diabetes), but it did not alter ET-1-induced vasoconstrictor response during euglycemia 
(Control / Cariporide, n = 9). *P < 0.05 vs. Control. (B) In the absence of cariporide, chronic 
hyperglycemia significantly increased U46619-induced constrictions of retinal venules (Control, 
n = 15; Diabetes, n = 14). Cariporide (1 µM) prevented the enhanced constriction of retinal 
venules to U46619 (Diabetes / Cariporide, n = 7) after chronic hyperglycemia (Diabetes), but it 
did not alter U46619-induced vasoconstrictor response during euglycemia (Control / Cariporide, 





Role of MAPKs in Hyperglycemia-enhanced Venular Constriction 
             The p38 MAPK inhibitor SB203580 did not influence basal tone (Fig. 16). However, it 
prevented the enhanced constrictions of retinal venules to ET-1 under chronic hyperglycemia 
without altering normal vasoconstrictor responses in euglycemia (Fig. 16). The ERK inhibitor 
PD98059 did not affect basal tone of venules or their vasoconstrictions to ET-1 after euglycemia 
or chronic hyperglycemia (Fig. 17). In the presence of JNK inhibitor SP600125, retinal venules 
lost about 70% of basal tone, and ET-1-induced vasoconstriction was attenuated during 
euglycemia and chronic hyperglycemia (Fig. 18). However, the ET-1-induced constriction after 
SP600125 treatment remained greater for vessels exposed to chronic hyperglycemia than to 
euglycemia (Fig. 18). In the presence of cariporide under chronic hyperglycemia, the additional 




























Figure 16. Role of p38 MAPK in enhanced ET-1-induced constriction of isolated retinal venules 
during chronic hyperglycemia. Venular diameters were recorded before (R: resting diameter) 
and after 30-minute treatment (T) with p38 MAPK inhibitor SB203580 (0.1 µM) prior to 
administration of ET-1. In the absence of SB203580, chronic hyperglycemia for 2 weeks in 
diabetic pigs significantly increased ET-1-induced constrictions of retinal venules (Control, n = 7; 
Diabetes, n = 7). SB203580 prevented the enhanced constriction of retinal venules to ET-1 
(Diabetes / SB203580, n = 6) after chronic hyperglycemia (Diabetes), but it did not alter ET-1-




















Figure 17. Role of ERK in enhanced ET-1-induced constriction of isolated retinal venules after 
chronic hyperglycemia. Venular diameters were recorded before (R: resting diameter) and after 
30-minute treatment (T) with ERK inhibitor PD98059 (10 µM) prior to administration of ET-1. 
The retinal venules from euglycemic pigs constricted concentration-dependently to ET-1 
(Control, n = 8), and the vasoconstriction to ET-1 was enhanced by chronic hyperglycemia 
(Diabetes, n = 10). PD98059 did not alter the constriction to ET-1 in vessels under euglycemia 
(Control / PD98059, n = 10) or the enhanced ET-1-induced vasoconstriction after chronic 




















Figure 18. Role of JNK in enhanced ET-1-induced constriction of isolated retinal venules during 
chronic hyperglycemia. Venular diameters were recorded before (R: resting diameter) and after 
30-minute treatment (T) with JNK inhibitor SP600125 (10 µM) prior to administration of ET-1. In 
the absence of SP600125, chronic hyperglycemia for 2 weeks in diabetic pigs significantly 
increased ET-1-induced constrictions of retinal venules (Control, n = 8; Diabetes, n = 12). 
SP600125 attenuated basal tone and constriction of retinal venules to ET-1 after euglycemia 
(Control / SP600125, n = 8) or chronic hyperglycemia (Diabetes / SP600125, n = 6). In the 
presence of SP600125, chronic hyperglycemia still significantly increased ET-1-induced 


















Figure 19. Influence of combined blockade of NHE and NCX or p38 MAPK on ET-1-induced 
constriction of isolated retinal venules during chronic hyperglycemia. Venular diameters were 
recorded before (R: resting diameter) and after 60-minute treatment (T) with NHE inhibitor 
cariporide (1 µM; n = 8) alone, cariporide and KB-R7943 (10 µM), or cariporide and SB203580 
(0.1 µM) prior to administration of ET-1. KB-7943 (n = 5) or SB203580 (n = 3) did not further 













             In the microcirculation, venular pressure plays an important role in governing fluid 
exchange across capillaries by regulating postcapillary resistance.3,4 Disruption of this 
homeostatic process can contribute to tissue edema during the development of diseases, 
including diabetic retinopathy. Recent evidence of high retinal venous pressure in patients with 
diabetic retinopathy7 suggests that elevation of vascular tone (i.e., vasoconstriction) in the 
venous microcirculation may promote retinal pathology. However, there is little information 
regarding vasomotor reactivity of retinal venules under normal and hyperglycemic states, 
especially the ability to constrict to endogenous substances. The main findings of the present 
study are that porcine retinal venules constrict in response to ET-1, U46619, and 
norepinephrine but not to angiotensin II and phenylephrine; vasoconstrictions to ET-1, U46619, 
and norepinephrine are augmented during acute and chronic hyperglycemia; and activation of 
the reverse-mode NCX and NHE appear to mediate these enhanced vasoconstrictor responses.  
             Direct evidence for vasoconstrictor function of retinal veins is limited to two recent 
studies showing that ET-1 elicits constriction of these vessels in pigs.21,49 To further our 
understanding of vasomotor regulation of retinal venules, we evaluated herein the 
responsiveness of these microvessels to ET-1 and other endogenous vasoconstrictors (Fig. 8). 
As shown previously, ET-1 elicited potent constriction of isolated retinal venules with threshold 
concentration of about 1 pM.21 We extended these findings to show for the first time the ability of 
retinal venules to constrict in response to activation of TBXA2R (U46619) and α-AR 
(norepinephrine) agonists. We also documented for the first time that hyperglycemia (both acute 
and chronic) enhances venular responses to these vasoconstrictors (Fig. 9). In contrast to other 
peripheral tissues,50,51 retinal venules appear to lack sufficient signaling for vasoconstriction via 
angiotensin II receptors and α1-ARs, because their specific agonists (angiotensin II and 
phenylephrine) evoked nominal changes in venular tone.  
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             We have recently shown that ET-1 elicits constriction of retinal venules by activating 
ETARs.21 The present study corroborates and extends this finding by demonstrating that 
pharmacological blockade of ETARs prevents constriction of retinal venules to ET-1 during 
hyperglycemia (Fig. 10A). In addition, both acute and chronic hyperglycemia enhanced ET-1-
induced constriction of retinal venules in a similar manner without altering the ETAR mRNA 
expression level (Fig. 10A-10C). It seems that hyperglycemia, while increasing vascular 
reactivity to ET-1, does not alter ETAR expression at least at the transcription level (Fig. 10C). 
Furthermore, the ability of acute exposure to high D-glucose but not high L-glucose to enhance 
ET-1-induced vasoconstriction indicates that the venular reactivity was specifically influenced by 
the functional hyperglycemia (A. 1). The combination of increased vasomotor activity of retinal 
venules to ET-1 and elevated ET-1 concentration in the vitreous of diabetic pigs in our study 
(Fig. 10D) suggests the potential contribution of this vasoactive peptide to the retinal venous 
pathology. Enhanced ET-1-induced constriction of retinal venules during diabetes could 
potentially increase retinal venous pressure and promote both edema and reduction in retinal 
perfusion pressure.5 This contention is supported by previous reports in diabetic patients of 
increased levels of ET-1 in the vitreous,12 elevated retinal venous pressure,7 and reduced retinal 
blood flow with macular edema.9 Furthermore, diminished blood flow in retinal veins of diabetic 
mice can be improved by treatment with an ETAR antagonist.52 Collectively, these previous 
observations along with our current findings suggest that enhanced retinal venular constriction 
to ET-1, via ETAR, may contribute to development of diabetic retinopathy. 
             TXA2 is a lipid product of arachidonic metabolism synthesized from thromboxane 
synthase by activated platelets and vascular cells.53,54 After cellular release, TXA2 can activate 
vascular smooth muscle TXA2Rs leading to vasoconstriction. Because TXA2 is quickly and 
spontaneously converted to the stable inactive TXB2 in aqueous solution, experimental studies 
commonly evaluate TXA2 function with the TXA2 analog U46619. This stable TXA2R agonist 
causes constriction of retinal arterioles,55 but its vasomotor influence on retinal venules has not 
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yet been determined. In the current study, U46619 elicited constriction of retinal venules with 
threshold concentration of about 0.1 nM under euglycemic conditions. Pharmacological 
blockade of TXA2Rs abolished U46619-induced vasoconstriction, indicating a functional 
vasomotor role for these receptors in porcine retinal venules (Fig. 11A). Moreover, acute and 
chronic hyperglycemia had no effect on the threshold concentration of U46619 to constrict 
retinal venules, but they both enhanced the maximum vasoconstriction (Fig. 9). Chronic 
hyperglycemia caused this augmented response without altering transcription of TXA2R mRNA 
(Fig. 11B). To our knowledge, this is the first evidence of TXA2R expression in the retinal 
microcirculation, and it extends previous reports detecting this receptor in human56 and rodent57 
neural retina tissue. It also appears that local production of TXA2 (estimated from the levels of 
stable TXA2 metabolite TXB2) within the vitreous is not altered within 2 weeks of diabetes (Fig. 
11C). However, we are unable to rule out the potential contribution from the vascular or serum 
level of TXA2 with hyperglycemia in view that elevated production of TXB2 from cultured bovine 
retinal endothelial cells and rabbit aorta after acute exposure to high glucose53 and chronic 
hyperglycemia,58 respectively, has been reported. Experimental type 1 diabetes in rats also 
significantly increases the platelet-generated TXB2 levels in the serum within 2 weeks of 
hyperglycemia.13 Moreover, intravenous administration of a TXA2 synthase inhibitor or a TXA2R 
antagonist can reverse the diminished retinal blood flow after 3-4 weeks of type 1 diabetes in 
rodents.59,60 Taken together, our present findings and previous evidence from other 
investigators support a potential role for TXA2R activation in retinal vascular disturbances during 
diabetes.  
             Although the retinal microcirculation apparently lacks autonomic innervation,61 the 
existence of α-ARs in retinal microvessels has been suggested based on pharmacological 
studies. The α1-AR agonist phenylephrine has been shown to constrict retinal arterioles in mice, 
cows, and rabbits.38,62,63 However, our findings showed that phenylephrine only elicited minor 
constriction of porcine retinal venules (Fig. 8), indicating that these vessels contain few or no 
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functional α1-ARs. Brimonidine, an α2-adrenergic receptor agonist, evokes constriction of 
isolated second-order arterioles from pigs.48 Comparably, we found constriction of second-order 
retinal venules to non-selective α-AR agonist norepinephrine, in a manner sensitive to the 
blockade of α2-ARs but not of α1-ARs (Fig. 12A). These results indicate that α2-ARs are 
responsible for constrictor action of norepinephrine in retinal venules. At the molecular level, we 
identified for the first time the expression of α1- and α2A-AR mRNAs in retinal venules (Fig. 12B-
12C). The α2A-AR expression in these vessels is consistent with the dominant expression of this 
α-AR subtype in porcine retinal arterioles48 and human retinal tissue.64 Similar to its effects on 
ET-1 and U46619, chronic hyperglycemia augmented norepinephrine-induced constriction of 
retinal venules without modifying expression of α-AR (α1 and α2A) mRNA levels (Fig. 12B-12C). 
This appears to be the first report of the direct impact of hyperglycemia on constriction of 
venules to norepinephrine during diabetes, and it is consistent with the increased 
norepinephrine-induced contraction of the large portal vein isolated from diabetic rats.65 
             A common mechanism for constriction of blood vessels involves entry of extracellular 
Ca2+ into the vascular smooth muscle.16 The transmembrane proteins that have been shown to 
contribute to regulation of Ca2+ entry into cells are reverse-mode NCXs,22 L-VOCCs,16 TRPC,18-
20 and CRAC channels.17 In our present study, the TRPC3 and CRAC channels did not appear 
to be involved in ET-1-induced vasoconstriction under euglycemia (A. 5). However, because the 
commercially available inhibitors of TRPC and CRAC channels are relatively non-selective, the 
involvement of TRPC or CRAC channels in vasoconstrictor responses to ET-1 remains unclear. 
On the other hand, the ability of low Na+ PSS exposure to cause constriction of retinal venules 
under euglycemia indicated that the reverse-mode NCX could be stimulated in these vessels (A. 
2). We proceeded to determine whether increased activity of reverse-mode NCX or L-VOCC 
contributes to the enhanced agonist-induced constriction of retinal venules during 
hyperglycemia by treating vessels with their cognate inhibitors. The pharmacological blockade 
of reverse-mode NCX (Fig. 13) prevented the enhanced constriction of retinal venules to ET-1, 
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U46619 and norepinephrine after exposure to acute and chronic hyperglycemia, suggesting 
possible role of NCX activation during diabetes. This conclusion is supported by the ability of 
two structurally different selective inhibitors of reverse-mode NCX, KB-R794342 (Fig. 13) and 
SEA040043 (A. 3), to block the hyperglycemia-enhanced constriction of retinal venules to ET-1. 
In contrast, L-VOCC blockade did not prevent the enhanced vasoconstriction, indicating that 
these channels were not involved in the altered vascular reactivity by hyperglycemia (A. 4). It 
does not appear that NCX contributes to agonist-induced venular constrictions during 
euglycemia, because NCX blockade had no effect on these responses. Interestingly, our data 
suggest that both L-VOCC and NCX contribute to the maintenance of basal tone of retinal 
venules, because their respective antagonists reduced the resting diameter to the same degree. 
At the molecular level, mRNAs for all three NCX isoforms (NCX1-3) were detected in porcine 
retinal venules, but chronic hyperglycemia did not affect their expression (A. 6). Future 
functional studies are warranted to evaluate whether a specific NCX isoform is activated in 
retinal venules by hyperglycemia.  
             A possible mechanism triggered by hyperglycemia upstream of NCX is activation of the 
NHE and PKC. PKC has been associated with vascular alteration during hyperglycemia.66 In our 
present study, we demonstrated that PKC was not involved in hyperglycemia-enhanced 
constriction of retinal venules to ET-1 (Fig. 14). On the other hand, because hyperglycemia can 
lead to intracellular acidosis and elevation of hydrogen ions, this could increase activity of the 
NHE to remove these ions from the cell in exchange for entry of sodium ions.67 As a result, 
intracellular sodium ion concentration may rise sufficiently to activate the reverse-mode NCX. In 
support of this notion, we found that NHE inhibitor cariporide abolished the enhanced 
constriction of retinal venules to ET-1 and U46619 under chronic hyperglycemia (Fig. 15). It 
appears that NHE and NCX are acting in series during chronic hyperglycemia because the 
combined treatment with their cognate inhibitors did not cause greater reduction in ET-1-
induced vasoconstriction than either treatment alone. Therefore, our findings support the ability 
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of hyperglycemia to activate an NHE/reverse-mode NCX pathway to enhance agonist-induced 
constriction of retinal venules. Our findings may provide insight into the ability of cariporide to 
prevent the apparent diabetes-induced increase in retinal microvascular resistance.45   
             The p38 MAPK activity of mesangial cells to ET-1 was enhanced after exposure to 
hyperglycemia,68 and the pathway linking ET-1-induced activity of NHE via p38 MAPK has also 
been demonstrated in Chinese hamster ovary cells.69 Our findings seem to support the 
mechanism of p38 MAPK-dependent activation of NHE in hyperglycemia-enhanced constriction 
of retinal venules to ET-1 (Fig. 16). However, we need to perform additional molecular 
investigations to confirm ET-1-induced activation of p38 linking to downstream NHE and NCX 
signaling in retina venules under hyperglycemia. Based on our current findings that 
pharmacological blockade of reverse-mode NCX and NHE prevented the increased constriction 
of retinal venules to multiple endogenous receptor pathways, therapeutic targeting of these 
specific proteins may help mitigate enhanced vasoconstrictors-induced constriction of retinal 
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A. 1. Stereospecific effect of glucose on ET-1-induced constriction of isolated porcine retinal 
venules. Constriction of retinal venules to ET-1 (0.1 nM) was significantly increased after 
intraluminal exposure to high D-glucose (25 mM; n = 8) for 2 hours. After intraluminal incubation 
with high L-glucose (20 mM L-glucose + 5 mM D-glucose; n = 4) for 2 hours, ET-1-induced 
















A. 2. Tracings of retinal venular constriction in response to rapid exposure to low-Na+ (~1.2 mM) 
physiological salt solution. KB-R7943 (10 µM; n = 5) abolished low-Na+-induced vasoconstriction 




















A. 3. Role of reverse-mode NCX in enhanced ET-1-induced constriction of isolated retinal 
venules after chronic hyperglycemia. Constriction of retinal venules to ET-1 (0.1 nM) was 
significantly increased after 2 weeks of diabetes in pigs. Reverse-mode NCX inhibitor SEA0400 
(10 µM) prevented the enhanced constriction of retinal venules to ET-1 after chronic 
hyperglycemia (Diabetes; n = 9), but it did not alter ET-1-induced vasoconstriction after 





A. 4. Role of L-VOCCs in ET-1-induced constriction of retinal venules after chronic and acute 
hyperglycemia. Venular diameters were recorded before (R: resting diameter) and after 30-
minute treatment (T) with L-VOCC inhibitor nifedipine prior to administration of ET-1. (A) The 
retinal venules from euglycemic pigs constricted concentration-dependently to ET-1 (Control, n 
= 10), and the vasoconstriction to ET-1 was enhanced by chronic hyperglycemia (Diabetes, n = 
7). Nifedipine (1 µM) did not alter the constriction to ET-1 in vessels from euglycemic pigs 
(Control / Nifedipine, n = 6) or the enhanced ET-1-induced vasoconstriction in chronic 
hyperglycemic pigs (Diabetes / Nifedipine, n = 4). *P < 0.05 vs. Control. (B) For retinal venules 
isolated from euglycemic pigs, the constriction to ET-1 in normal 5 mM D-glucose (Control, n = 
8) was significantly enhanced by acute exposure to 25 mM D-glucose (High Glucose, n = 7). 
Nifedipine did not affect either the vasoconstriction to ET-1 in normal level of glucose (Control / 
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Nifedipine, n = 7) or the enhanced vasoconstriction in acute hyperglycemia (High Glucose / 


















A. 5. Roles of TRPC3 and CRAC channels in vasoconstriction of isolated retinal venules to ET-
1. Administration of TRPC3 antagonist Pyr3 (10 µM; n=3) or CRAC channels inhibitor BPT2 (1 
µM; n=6) did not alter ET-1-induced (0.1 nM) constriction of retinal venules during euglycemia.  
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A. 6. Real-time PCR analysis of mRNA expression of NCX isoforms in porcine retinal venules 
and neural retina tissue. Equal amounts of total RNA isolated from porcine retinal venules and 
neural retina tissue after 2 weeks of euglycemia (Control) and chronic hyperglycemia (Diabetes) 
were reverse transcribed and then analyzed by real-time PCR for detection of NCX1-3 isoforms 
and GAPDH mRNAs. The NCX1-3 isoforms transcripts were normalized to GAPDH expression 
and presented as relative mRNA expression. (A) NCX 1-3 isoform expressions in retinal venules 
were not different between control (n = 9 for each isoform) and diabetes (n = 12 for each 
isoform) samples. (B) The NCX isoform expressions in neural retina tissue were not altered by 




IV. ACUTE HYPERGLYCEMIA ENHANCES ENDOTHELIN-1-INDUCED 
CONSTRICTION OF HUMAN RETINAL VENULES 
 
Introduction 
             Diabetes mellitus is a global epidemic and leads to a range of macrovascular and 
microvascular complications. Diabetic retinopathy is one of the specific microvascular 
complications of diabetes and is a leading cause of vision impairment and blindness in working-
age adults.1,2 Accumulating evidence has shown that vitreous humor, plasma and ocular levels 
of endothelin-1 (ET-1) are elevated in diabetes, especially in diabetic patients with proliferative 
diabetic retinopathy.3-5 
             ET-1 is a potent vasoactive peptide comprised of 21 amino acids and plays important 
roles in many biological functions, including vasoconstriction, cardiovascular remodeling, tissue 
inflammation, and cell proliferation.3,6-9 Since overproduction of ET-1 is known to contribute to 
the pathogenesis of many diseases, it is clinically important to understand the mechanism of 
retinal venular constriction to ET-1 in physiology and pathophysiology. Although the retinal 
microcirculation lacks extrinsic innervation,10 the identification of autonomic receptors on the 
walls of retinal vessels has been demonstrated in many species, including human.11-13 Among 
those receptors, α1 adrenergic and α2 adrenergic receptors generally mediate vasoconstriction 
in the vascular system. Our previous studies demonstrated that norepinephrine elicited α2 
adrenergic receptor-dependent constriction in porcine retinal venules (Chapter III). However, 
there is no study related to norepinephrine-induced vasomotor activity in human retinal venules. 
             In the retinal microcirculation, the arterioles through changes in their vasomotor tone 
and resistance play an important role in governing retinal blood flow.14 At the level of retinal 
venules, changes venular resistance influence hydrostatic pressure and fluid homeostasis of 
upstream capillaries.15,16 Constriction of retinal venules leads to increased retinal venous 
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resistance and pressure, which could subsequently reduce retinal perfusion and promote 
edema under disease states such as diabetes.17,18 However, in contrast to retinal arterioles, our 
understanding of factors affecting vasomotor activity of retinal venules is rather sparse.19,20 Our 
previous study found that ET-1 causes marked constriction of porcine retinal venules through 
ETARs and extracellular Ca2+ influx independent of L-type voltage operated Ca2+ channels.19 
Also, we have shown that hyperglycemia augmented porcine venular constriction to ET-1, 
U46619, and norepinephrine (Chapter III). Intriguingly, there is a growing body of evidence 
indicating a connection between retinal venous pressure and diabetic retinopathy.21 However, 
there has been no study addressing whether vasomotor function of human retinal venules is 
affected by hyperglycemia. We addressed these issues by examining the vasomotor response 
to ET-1 and norepinephrine in human retinal venules isolated from eyes donated by patients 
undergoing enucleation. Because elevated plasma glucose level is one of major risk factors and 
contributors to the development of diabetic retinopathy,22,23 we also investigated whether 
exposure of human retinal venules to high glucose influences ET-1-induced vasoconstriction.  
 
Methods 
Human Subjects Study 
             Retinal tissues were obtained from 1 male (81 years old) and 4 female patients (45, 62, 
69, and 69 years old) undergoing enucleation after informed consent and with approval from the 
Baylor Scott & White Health Institutional Review Board. The research followed the tenets of the 
Declaration of Helsinki. Eyes were enucleated from the 5 patients due to ocular melanoma. 
Immediately after enucleation, an eye cap was removed and transferred to a moist chamber on 
ice for microvessel isolation. The remaining ocular tissue with the tumor was placed in 10% 




Isolation and Cannulation of Human Retinal Venules 
             Techniques for identifying and isolating human retinal microvessels were the same as 
our previous studies.24-26 The ocular tissue was placed in a cooled dissection chamber (~8°C) 
containing a physiological salt solution (PSS; 145.0 mM NaCl, 4.7 mM KCl, 2.0 mM CaCl2, 1.17 
mM MgSO4, 1.2 mM NaH2PO4, 5.0 mM glucose, 2.0 mM pyruvate, 0.02 mM EDTA, and 3.0 mM 
MOPS) with 0.1% albumin. Single retinal venules (1 to 1.5 mm in length without side branches) 
were carefully dissected with the aid of a stereomicroscope (model SZX12; Olympus, Melville, 
NY, USA). After the removal of any remaining neural/connective tissues, the venule was 
transferred to a polymethylmethacrylate vessel chamber containing PSS-albumin solution 
equilibrated with room air at ambient temperature. Both ends of the venule were cannulated 
using glass micropipettes filled with PSS containing 1% albumin, and the outside of the venules 
were securely tied to the pipettes with 11-0 ophthalmic suture (Alcon, Fort Worth, TX, USA). 
Vessels were pressurized to 5 cmH2O (4 mmHg) intraluminal pressure by two independent 
pressure reservoirs and allowed to develop basal tone before study. This intraluminal pressure 
was chosen based on our previous study in porcine retinal venules.19 Vasomotor activity of 
isolated venules was recorded using videomicroscopic techniques throughout the experiments. 
Experimental Protocols 
             Vasomotor Responses to ET-1 and Norepinephrine: Cannulated human retinal venules 
were bathed in PSS-albumin at 36° to 37°C to allow development (~90 minutes) of basal tone. 
The vasomotor response to cumulative administration of ET-1 (1 pM to 10 nM; Bachem, 
Torrance, CA)27 or norepinephrine (1 nM to 10 µM; Cayman Chemical, Ann Arbor, MI) was then 
evaluated. Retinal venules were exposed to each concentration of ET-1 or norepinephrine for 
10 minutes until a stable diameter was established. 
             High Glucose Study: To examine the influence of glucose on vasomotor responses, 
human retinal venules were isolated from enucleated patients and then the vessels were treated 
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with normal glucose (5 mM ≈ 90 mg/dl) or high glucose (25 mM ≈ 450 mg/dl) intraluminally for 2 
hours as described in our previous study.28 The vasomotor reactivity in response to ET-1 was 
then assessed after the 2-hour exposure to normal or high glucose. Osmolarity was maintained 
at a normal level by reducing the NaCl concentration in the high glucose-treated vessels.  
Chemicals 
             ET-1 was dissolved in water, and norepinephrine was dissolved in dimethyl sulfoxide. 
Subsequent concentrations of these drugs were diluted in PSS. The final concentration of 
dimethyl sulfoxide was not more than 0.1%. Vehicle control studies indicated that this final 
concentration of solvent had no effect on vessel viability, vasoconstrictor responses, or 
maintenance of basal tone (data not shown). 
Data Analysis 
             At the end of each functional experiment, the vessel was relaxed with 0.1 mM sodium 
nitroprusside in EDTA (1 mM)-Ca2+-free PSS to obtain its maximal diameter at 5 cmH2O 
intraluminal pressure. Diameter changes in response to agonists were normalized to the resting 
diameter and expressed as percentage changes in diameter. Data are reported as mean ± 
SEM, and n represents the number of vessels (1-2 vessels per patient per treatment group for 
functional studies). The repeated measures two-way analysis of variance followed by Bonferroni 
multiple-range test was used to determine the significance of experimental interventions, as 
appropriate (GraphPad Prism, Version 6.0, GraphPad Software, La Jolla, CA, USA). P < 0.05 
was considered significant. 
 122 
Results 
Human Retinal Venular Constriction to ET-1 and Norepinephrine 
             Human retinal venules (total 11 vessels in Figure 20) were isolated and pressurized at 5 
cmH2O with average maximum diameter of 64 ± 4 µm. These vessels developed stable basal 
tone by constricting to about 89% of maximum diameter within 60 minutes at 36-37°C. In one 
cohort, administration of ET-1 caused constriction of retinal venules in a concentration 
dependent manner (Figure 20A). In the other cohort, administration of norepinephrine also 
caused constriction of retinal venules in a concentration-dependent manner (Figure 20B). The 
threshold concentrations of ET-1 and norepinephrine for venular constriction were about 1 pM 










Figure 20. Vasomotor response of isolated and pressurized human retinal venules to ET-1 and 






High Glucose Enhances ET-1-Induced Constriction of Human Retinal Venules 
             Retinal venules exposed intraluminally to normal glucose and high glucose developed a 
comparable level of basal tone. The ET-1-induced constriction of venules from 10 pM to 1 nM 












Figure 21. Effect of high glucose on the vasoconstrictor response of isolated and pressurized 
human retinal venules to ET-1. The vasoconstriction to ET-1 from 10 pM to 1 nM was 
significantly greater after 2-hour intraluminal exposure to high glucose (Control, n = 6; High 







             It is generally accepted that vasomotor activity of the arterioles primarily regulates 
retinal blood flow within the retinal circulation, and the venules maintain ocular fluid homeostasis 
and mediate postcapillary pressure linking to retinal pathogenesis, including retinal edema. 
There is an emerging concept depicting a connection between diabetic retinopathy and higher 
retinal venous pressure,21 so abnormal vasoreactivity of retinal venules during retinal 
pathogenesis is conceivable. However, there is little information regarding the vasomotor 
reactivity of retinal venules, especially the vasoconstrictor responses of human retinal venules. 
Our previous study provided the information of vasomotor reactivity of porcine retinal venules to 
vasoconstrictors (ET-1, U46619, and norepinephrine) during acute and chronic hyperglycemia 
(Chapter III). The salient findings of the present study show similar vasoconstrictor responses of 
human retinal venules to ET-1 and norepinephrine (Figure 20), with enhanced vasoconstriction 
to ET-1 during short-term exposure to high glucose (Figure 21). 
             Despite the lack of extrinsic innervation in the retinal circulation,10 autonomic receptors 
have been identified on the walls of retinal vessels.11-13 Among these, α2A adrenergic receptors 
are the predominant α-adrenergic receptor subtype in human ocular tissue homogenates,34 and 
we observed predominantly α2 adrenoceptor-dependent constriction of porcine retinal venules to 
norepinephrine in our previous study (Chapter III). Accumulating evidence has shown that 
vitreous humor, plasma and ocular levels of ET-1 are elevated in diabetes, especially in diabetic 
patients with proliferative diabetic retinopathy,3,4,29,30 and associate with reduced retinal blood 
flow during the early stage of diabetes.31-33 Our previous study also detected elevated ET-1 
protein levels in the porcine vitreous humor, and ET-1 and norepinephrine elicited enhanced 
constriction of porcine retinal venules under hyperglycemia (Chapter III). The present 
investigation is the first to observe vasomotor function of isolated human retinal venules, with 
vasoconstrictions to ET-1 and norepinephrine. The ability of high glucose to enhance 
constriction of human retinal venules to ET-1, as observed previously with porcine vessels, 
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indicates the importance of a considering vasoreactivity of human retinal venules in ocular 
pathogenesis, especially diabetes. 
             The limitation of the present study is the inability to determine whether vascular disease 
or melanoma influences the results. Most patients were middle aged to elderly and had taken 
several types of medicine that could influence vascular function. Our previous study in human 
retinal arterioles addressed the potential influence of these factors (age, medicine-taken, and 
melanoma).25 It is worth noting that we evaluated human retinal venules with an average 
maximum diameter of 64 µm in the present study. However, the maximum diameter of porcine 
retinal venules that we examined previously was about 130 µm.19 The human retinal venules 
developed comparable but slightly greater tone (constricted to about 89% of maximum 
diameter) than did porcine retinal venules (constricted to about 93% of maximum diameter). In 
contrast, human retinal venules displayed similar vasoconstrictor responses to ET-1 and 
norepinephrine as observed with porcine retinal venules in our previous study (Chapter III), 
which strengthens use of the porcine eye to study the human retinal microcirculation.  
             In conclusion, we found that isolated human retinal venules develop stable basal tone 
and constrict in response to ET-1 and norepinephrine. We also showed that high glucose does 
not influence basal tone but enhances ET-1-induced constriction of human retinal venules. Our 
findings provide the initial insight into the impact of vasoconstrictor agonists on tone of retinal 
venules of humans under normal and high glucose conditions, which may indicate key 
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             I demonstrated that extracellular Ca2+ entry via L-VOCCs is essential for developing and 
maintaining basal tone of porcine retinal venules. ET-1 causes significant constriction of retinal 
venules by activating ETARs and extracellular Ca2+ entry independent of L-VOCCs. Activation of 
ROCK signaling, without involvement of PKC, appears to mediate venular constriction to ET-1 in 
the porcine retina. Retinal venules also constrict to norepinephrine and TXA2 analog U46619. 
On the other hand, angiotensin II and a1-adrenergic agonist phenylephrine fail to elicit 
vasomotor responses of retinal venules. Acute and chronic (diabetes) hyperglycemia enhance 
retinal venular constriction to ET-1, norepinephrine, and U46618 without altering the mRNA 
expression level of corresponding receptors. The enhanced vasoconstrictions appear to be 
mediated by the activation of reverse-mode NCX and the NHE through p38 MAPK signaling 
(Fig. 22). This enhanced responsiveness might be important for ET-1 because the vitreous 
concentration of this peptide is significantly elevated to the level sufficient to cause venular 
constriction in hyperglycemia/diabetes. The results from human retinal venular studies also 
support the alteration of venular reactivity to ET-1 when hyperglycemic insult is imposed. In 
conjunction with previous studies on the porcine retinal arterioles, the vasomotor activity of 
porcine retinal venules appears to be comparable to that of human, supporting use of the 
porcine eye for studying the human retinal microcirculation. The functional alteration of venular 
activity in response to several endogenous vasoconstrictors in early diabetes might aggravate 
the development of venous hypertension and retinal edema in the late stage of diabetic 
retinopathy, in addition to physical disruption of the retinal microcirculation. Consideration of 
correcting vasomotor function of retinal venules, as well as arterioles, with effective therapeutic 















Figure 22. Schematic diagram of p38 MAPK-NHE-NCX pathway for enhanced constriction of  




             In my study, the p38 MAPK-dependent activation of NHE-NCX signaling is implicated in 
diabetes-related enhancement of constriction of retinal venules to ET-1 without the involvement 
of L-type Ca2+ channels. However, the p38 MAPK-dependent activity of NHE and the detailed 
signal transduction pathways involved in ET-1-induced constriction of retinal venules remain 
unknown. Moreover, our results showed that ET-1-elicited constriction of retinal venules is 
predominantly mediated by the activation of ETAR. The ETARs, which belong to the G protein-
coupled receptors (GPCRs) superfamily, can induce formation of second messengers, and 
subsequently lead to activation of Ca2+ channels (such as voltage-dependent cation channels 
and CRAC channels) accompanied by an influx of Ca2+ from the extracellular medium.1,2 In 
addition, ET-1 can possibly stimulate Na+ influx via the opening of TRPC, and consequently 
elevate cytoslic Na+i for membrane depolariation and then trigger the opening of L-VOCCs and 
activate the reverse-mode NCX.3-5 Although these signaling events do not contribute to the 
vasoconstriction, their activations might modulate the vasomotor activity and reactivity to various 
agonists. Therefore, the detailed studies of the upstream signals on CRAC channels- ,TRPC-, 
or NCX-NHE- related vasomotor activity contributing to enhanced retinal venular responses to 
endogenous vasoconstrictors need to be further investigated. Although my studies suggest the 
link between NHE and NCX in enhanced vasoconstriction to ET-1, U46619 and norepinephrine, 
the corresponding changes in intracellular level of Na+ and Ca2+ in diabetic vessels during ET-1 
stimulation need to be verified. Moreover, the mechanism responsible for p38 MAPK activation 
during hyperglycemic insult remains to be explored. Although I did not examine whether the 
endothelial function, in terms of NO-mediated vasodilation, is altered by hyperglycemia, multiple 
reports have demonstrated the endothelial dysfunction in the arterial network of diabetic 
animals. It is worth investigating the impact of diabetes on the endothelial function of retinal 
venules because inflammatory leukocytes mainly interact with the vasculature, depending upon 
the endothelial integrity and function, in the venular circulation. The endothelial NO deficiency 
 133 
apparently facilitates the development of inflammation and promotes activation of the immune 
system in the venular circulation. However, it is unclear whether hyperglycemia/diabetes could 
alter endothelial function in the venular circulation, in addition to the enhancement of 
vasoconstrictor function as I observed. It would be also interesting to know whether the altered 
vasomotor activity of retinal venules is reversible after hyperglycemic insult is removed. 
Answers to these issues could enhance our understanding on the pathogenesis of diabetic 
retinopathy, especially the alteration of retinal blood flow regulation and the disturbance of fluid 
homeostasis via the transvascular pathway. 
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